

Publication (研究発表業績)

[Original research papers] (英文論文)

- 1) Matsumoto T, Ohashi Y, Morita S, Kobayashi K, Shibuya M, Yamaji Y, Eguchi K, Fukuoka M, Nagao K, Nishiwaki Y, Niitani H. The Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD): Validity and Reliability in Japanese Patients with Advanced Non-Small-Cell Lung Cancer. *Quality of Life Research* 11: 483-493, 2002.
- 2) Fukui T, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Morita S, Ogihara T, Fukiyama K, Fujishima M, Saruta T. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-risk Hypertensive Patients. Rationale, Design, and Methods. *Hypertension Research* 26: 979-90, 2003.
- 3) Morita S, Kobayashi K, Eguchi K, Matsumoto T, Shibuya M, Yamaji Y, Sakamoto J, Ohashi Y. Influence of Clinical Parameters on Quality of Life During Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer: Application of a General Linear Model. *Japanese Journal of Clinical Oncology* 33: 470-476, 2003.
- 4) Sakamoto J, Morita S, T. Yumiba, H. Narahara, K. Kinoshita, Y. Nakane, H. Imamoto, H. Shiozaki. A Phase II Clinical Trial to Evaluate the Effect of Paclitaxel in Patients with Ascites Caused by Advanced or Recurrent Gastric Carcinoma: A New Concept of Clinical Benefit Response for Non-Measurable Type of Gastric Cancer. *Japanese Journal of Clinical Oncology* 33: 238-240, 2003.
- 5) Morita S, Ohashi Y, Kobayashi K, Matsumoto T, Eguchi K, Shibuya M, Yamaji Y, Fukuoka M, Nagao K and Niitani H. Individually Different “Weights” of Quality of Life Assessment in Patients With Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Epidemiology* 56: 744-751, 2003.
- 6) Morita S, Kobayashi K, Ohashi Y, Eguchi K, Shibuya M, Matsumoto T, Yamaji Y, Nagao K, Niitani H. Weekly assessment of quality of life in patients with advanced non-small-cell lung cancer during chemotherapy in a randomized phase III trial. *Annals of Cancer Research and Therapy* 12: 105-117, 2004.
- 7) Morita S, Ohashi Y, Hirakawa K, Nakata B, Saji S, Sakamoto J. Phase I/II Study of Combination Therapy of Oral Fluorinated Pyrimidine Compound S-1 with Low-dose Cisplatin in Patients with Unresectable and/or Recurrent Advanced Gastric Cancer: A Novel Study Design to Evaluate Safety and Efficacy. *Japanese Journal of Clinical Oncology* 34: 159-161, 2004.
- 8) Morita S, Toi M, Kobayashi T, Ito Y, Hozumi Y, Ohno S, Iwata H, Sakamoto J. Application of a Continual Reassessment Method to a Phase I Clinical Trial of Capecitabine in Combination

- with Cyclophosphamide and Epirubicin (CEX) for Inoperable or Recurrent Breast Cancer. Japanese Journal of Clinical Oncology 34: 104-106, 2004.
- 9) Sakamoto J, Morita S, Kodera Y, Rahman M, Nakao, A. Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol 54: S25-S31, 2004.
 - 10) Noguchi W, Ohno T, Morita S, Aihara O, Tsujii H, Shimozuma K, Matsushima E. Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp) for Japanese patients with cancer. Supportive Care in Cancer 12: 240-245, 2004.
 - 11) Rahman M, Morita S, Fukui T, Sakamoto J. Physicians' reasons for not entering their patients in a randomized controlled trial in Japan. Tohoku J. Exp. Med 203: 105-109, 2004.
 - 12) Rahman M, Morita S, Fukui T, Sakamoto J. Physicians' Choice in Using Internet and Fax for Patient Recruitment and Follow-up in a Randomized Controlled Trial. Methods of Information in Medicine 43: 288-92, 2004.
 - 13) Komatsu H, Fujimoto S, Sato Y, Hara S, Yamada K, Morita S, Eto T. Point of No Return (PNR)' in Progressive IgA Nephropathy: Significance of Blood Pressure and Proteinuria Management Up to PNR. Journal of Nephrology 18: 690-695, 2005.
 - 14) Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y, Macdonald JS. A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial. Japanese Journal of Clinical Oncology 35: 672-675, 2005.
 - 15) Ueda Y, Yamagishi H, Ichikawa D, Morii J, Koizumi K, Kakihara N, Shimotsuma M, Takenaka A, Yamashita T, Kurioka H, Nishiyama M, Morita S, Nakamura K, Sakamoto J. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 69: 261-268, 2005.
 - 16) Morita S, Fukuhara S, Akizawa T, Asano Y, Kurokawa K. Study Design and Methods for a Clinical Trial for an Oral Carbonaceous Adsorbent Used to Prevent the Progression of Chronic Kidney Disease (CAP-KD). Clin Exp Nephrol 9: 219-227, 2005.
 - 17) Rahman M, Morita S, Fukui T, Sakamoto J. Physicians' Attitudes towards Reasons for Participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial. Journal of Epidemiology 15: 38-40, 2005.
 - 18) Morita S, Kobayashi K, Eguchi K, Matsumoto T, Shibuya M, Yamaji Y, Ohashi Y. Analysis of Incomplete Quality of Life Data in Advanced Stage Cancer: A Practical Application of Multiple Imputation. Quality of Life Research 14: 1533-1544, 2005.
 - 19) Kaptein AA, Morita S, Sakamoto J. Quality of life in gastric cancer. World J Gastroenterol 11: 3189-3196, 2005.

- 20) Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M, Tabuena R, Chin K, Mio T, Ito Y, Muro S, Hirai T, Morita S, Fukuhara S, Mishima M. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. *Thorax* 60: 277-81, 2005.
- 21) Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T, Musha N, Miyashita K, Konno H, Nagata N, Saito N, Usuki H, Ozaki N, Nonaka Y, Iwashita T, Miyashita Y, Oba K, Morita S, Sakamoto J. Multicenter Phase II Trial of Combination Chemotherapy with Weekly Paclitaxel and 5-Fluorouracil for the Treatment of Advanced or Recurrent Gastric Carcinoma. *Journal of Chemotherapy* 19: 444-450, 2007.
- 22) Matsui T, Omura K, Kawakami K, Morita S, Sakamoto J. Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. *Oncol Rep* 16: 1111-1115, 2006.
- 23) Oba K, Morita S, Rahman M, Sakamoto J. Factors associated with compliance and non-compliance by physicians in a large-scale randomized clinical trial. *Trials* 7: 1-7, 2006.
- 24) Fukui T, Rahman M, Morita S, Sakamoto J. Informed Consent in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial: A Survey of Collaborating Physicians. *Hypertens Res* 29: 471-474, 2006.
- 25) Ando K, Morita S, Higashi T, Fukuhara S, Watanabe S, Park S, Kikuchi M, Kawano K, Wasada I, Hotta T. Health-related quality of life among asymptomatic women with iron-deficiency anemia in Japan. *Quality of Life Research* 15: 1559-63, 2006.
- 26) Morita S, Sakamoto J. Application of an adaptive design to a randomized phase II selection trial in gastric cancer. *Pharmaceutical Statistics* 5: 109-118, 2006.
- 27) Kamei M, Morita S, Hayashi Y, Kanmura Y, Kuro M. Carvedilol versus metoprolol for the prevention of atrial fibrillation after off-pump coronary bypass surgery: Rationale and design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT). *Cardiovasc Drug Ther* 20: 219-27, 2006.
- 28) Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer in Japan; A meta-analysis of centrally randomized controlled clinical trials. *Journal of Chemotherapy* 18: 311-318, 2006.
- 29) Morita S, Kobayashi M, Oba K, Ichihara T, Nakao A, Sakamoto J. Truth-telling to Patients with Advanced Cancer: A Comparison between Leading Institutions, General City Hospitals, and Private General Practitioners in Japan. *Ann. Cancer Res. Therap* 1: 1-11, 2006.
- 30) Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J. A phase I/II

- trial of a WT1 (Wilms' Tumor Gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. *Jpn J Clin Oncol* 36: 231-236, 2006.
- 31) Fukui T, Rahman M, Shimbo T, Morita S, Sakamoto J. Recruitment of Patients for a Clinical Trial: Factors on Physician Side and Reason on Patient Side. *Intern Med* 45: 511-514, 2006.
 - 32) Takahashi N, Kikuchi S, Konno S, Morita S, Suzukamo Y, Green J, Fukuhara S. Discrepancy between disability and the severity of low-back pain: demographic, psychological, and employment-related factors. *Spine* 31: 931-939, 2006.
 - 33) Matsuyama Y, Morita S. Estimation of the average causal effect among subgroups defined by posttreatment variables. *Clinical Trials* 3: 1-9, 2006.
 - 34) Morita S, Fukuhara S, Akizawa T, Asano Y, Koshikawa S, Koide K, Kurokawa K. Prognostic Factors for a Composite Endpoint of Renal Outcomes in patients with Chronic Kidney Disease. *Ther Apher Dial* 10: 72-77, 2006.
 - 35) Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y. Efficacy of Adjuvant Immunochemotherapy with Polysaccharide K for Patients with Curatively Resected Colorectal Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials. *Cancer Immunol Immunother* 55: 404-411, 2006.
 - 36) Noguchi W, Morita S, Ohno T, Aihara O, Tsujii H, Shimosuma K, Matsushima E. Spiritual Needs in Cancer Patients and Spiritual Care based on Logotherapy. *Supportive Care in Cancer* 14: 65-70, 2006.
 - 37) Kurita M, Shimosuma K, Morita S, Fujiki Y, Ishizawa K, Eguchi H, Saito Y, Ushiorozawa N, Wasada I, Ohashi Y, Eguchi K. Clinical Validity of the Japanese Version of the Functional Assessment of Cancer Therapy-Anemia Scale. *Support Care Cancer* 15: 1-6, 2007.
 - 38) Enkhbold S, Tugsdelger S, Morita S, Sakamoto J, Hamajima N. HIV/AIDS related knowledge and risk behaviors among female sex workers in two major cities of Mongolia. *Nagoya J Med Sci* 69: 157-65, 2007.
 - 39) Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer. *Oncology* 72: 330-7, 2007.
 - 40) Yamazaki S, Fukuhara S, Suzukamo Y, Morita S, Okamura T, Tanaka T, Ueshima H. Lifestyle and work predictors of fatigue in Japanese manufacturing workers. *Occup Med (Lond)* 57: 262-9, 2007.
 - 41) Morita S, Nakata B, Tsuji A, Mitachi Y, Shirasaka T, Saji S, Ohashi Y, Sakamoto J, Hirakawa K. A Phase I/II Study of Combination Therapy of the Oral Fluorinated Pyrimidine Compound S-1 with Low-dose Cisplatin in Patients with Advanced Gastric Cancer: Analysis of Phase I Data Using a Continual Reassessment Method. *Jpn J Clin Oncol* 37: 924-9, 2007.

- 42) Urushihara H, Fukuhara S, Tai S, Morita S, Chihara K. Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult- and childhood-onset Japanese hypopituitary adults with growth hormone deficiency during GH replacement. *European Journal of Endocrinology* 156: 637-645, 2007.
- 43) Yamada S, Takeda S, Fujii T, Nomoto S, Kanazumi N, Sugimoto H, Kasuya H, Kodera Y, Nagasaka T, Morita S, Nakao A. Clinical Implications of Peritoneal Cytology in Potentially Resectable Pancreatic Cancer: Positive Peritoneal Cytology May Not Confer an Adverse Prognosis. *Annals of Surgery* 246: 254-258, 2007.
- 44) Morita S, Baba H, Tsuburaya A, Takiuchi H, Matsui T, Maehara Y, Sakamoto J. A Randomized Phase II Selection Trial in Patients with Advanced/Recurrent Gastric Cancer: Trial for Advanced Stomach Cancer (TASC). *Jpn. J. Clin. Oncol* 37: 469-472, 2007.
- 45) Morita S, Toi M, Saji S, Iwata H, Ohno S, Ito Y, Kobayashi T, Hozumi Y, Sakamoto J. Practical application of the Continual Reassessment Method to a phase I dose-finding trial in advanced breast cancer. *Drug Information Journal* 41: 691-700, 2007.
- 46) Morita S, Kaptein AA, Oba K, Sakamoto J. The Domain Structure of the EORTC QLQ-STO22 Supported by Japanese Validation Data. *Psycho-Oncology*. *Psychooncology* 17: 474-9, 2008.
- 47) Morita S, Thall PF, Müller P. Determining the Effective Sample Size of a Parametric Prior. *Biometrics* 64: 595-602, 2008.
- 48) Fukuhara S, Akizawa T, Morita S, Koshikawa S and the KRN321 A08 Study group. Quality-of-life improvements in dialysis patients receiving darbepoetin alpha (KRN 321). *Ther Apher Dial* 12: 72-7, 2008.
- 49) Takahashi K, Chin K, Nakamura H, Morita S, Sumi K, Nakamura T, Matsumoto H, Niimi A, Fukuhara S, Yodoi J, Mishima M. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. *Antioxidants & Redox Signaling*. *Antioxid Redox Signal* 10: 715-26, 2008.
- 50) Cho H, Tsuburaya A, Sakamoto J, Morita S, Oba K, Yoshikawa T, Miyajima N. A Randomized Phase II Trial of Preoperative Exercise to Reduce Operative Risk in Gastric Cancer Patients with Metabolic Syndrome: Adjuvant Exercise for General Elective surgery (AEGES) Study Group. *Jpn J Clin Oncol* 38: 71-3, 2008.
- 51) Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Morita S, Sakamoto J, Sugiyama H, Yoshimine T. Vaccination with a single kind of WT1 peptide efficiently induces tumor stabilization in patients with recurrent glioblastoma, leading to their favorable progression-free survival: phase II study results. *J Neurosurgery* 108: 963-71, 2008.

- 52) Kanai M, Morita S, Matsumoto S, Nishimura T, Hatano E, Yazumi S, Sasaki T, Yasuda H, Kitano T, Misawa A, Ishiguro H, Yanagihara K, Ikai I, Doi R, Fukushima M: A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. *Annals of Oncology* 20: 1397-1401, 2008.
- 53) Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Watanabe T, Bain S, Hausheer FH. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. *Japanese Journal of Clinical Oncology* 38: 748-54, 2008.
- 54) Kobayashi K, Morita S, Shimonagayoshi M, Kobayashi M, Fujiki Y, Uchida Y, Yamaguchi K. Effects of socioeconomic factors and cancer survivors' worries on their quality of life (QOL) in Japan. *Psycho-Oncology* 17: 606-11, 2008.
- 55) Nalongsack S, Yoshida Y, Morita S, Sosouphanh K, Sakamoto J. Knowledge, attitude and practice regarding dengue among people in Pakse, Laos. *Nagoya Journal of Medical Science* 71: 29-37, 2009.
- 56) Harun-Or-Rashid M, Khatun UF, Yoshida Y, Morita S, Chowdhury N, Sakamoto J. Iron and iodine deficiencies among under-2 children, adolescent girls, and pregnant women of Bangladesh: association with common diseases. *Nagoya Journal of Medical Science* 71: 39-49, 2009.
- 57) Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). *Support Care Cancer* 17: 1071-80, 2009.
- 58) Ishikawa T, Shimizu S, Katayama K, Chishima T, Hamaguchi Y, Doi T, Tanabe M, Kasahara A, Yamaguchi N, Narui K, Ohta I, Matsumoto C, Shimizu D, Kito A, Suda T, Inaba M, Asaga T, Momiyama N, Ichikawa Y, Yoshimoto M, Morita S, Shimada H. Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan. *Anticancer Research* 29: 1515-20, 2009.
- 59) Kosuge M, Kimura K, Morita S, Kojima S, Sakamoto T, Ishihara M, Asada Y, Tei C, Miyazaki S, Sonoda M, Tsuchihashi K, Yamagishi M, Shirai M, Hiraoka H, Honda T, Ogata Y, Ogawa H; Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Combined prognostic utility of white blood cell count, plasma glucose, and glomerular filtration rate in patients undergoing primary stent placement for acute myocardial infarction. *American Journal of Cardiology* 103: 322-7, 2009.
- 60) Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH: Feasibility and validity of the

- Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. *Support Care Cancer* 17: 1483-1491, 2009.
- 61) Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group: Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. *American Journal of Kidney Diseases* 54: 459-467, 2009.
 - 62) Kamiya Y, Kikuchi T, Inagawa G, Miyazaki H, Miura M, Morita S, Goto T: Lidocaine concentration in cerebrospinal fluid after epidural administration: a comparison between epidural and combined spinal-epidural anesthesia. *Anesthesiology* 110: 1127-1132, 2009.
 - 63) Fukui T, Shimokawa T, Manabe S, Morita S, Takanashi S: Prior inferior myocardial infarction has worse early outcomes in patients undergoing coronary artery bypass grafting than prior anterior myocardial infarction. *The Annals of Thoracic Surgery* 87: 475-480, 2009.
 - 64) Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. *Clinical Cancer Research* 15: 4493-4498, 2009.
 - 65) Morita S, Thall PF, Bekele BN, Mathew P. A Bayesian hierarchical mixture model for platelet derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. *Journal of the Royal Statistical Society, Series C (Applied Statistics)* 59: 19-34, 2009.
 - 66) Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. *Journal of Clinical Oncology* 27: 1394-1400, 2009.
 - 67) Kono T, Mishima H, Shimada M, Morita S, Sakamoto J; GONE Investigators: Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study). *Japanese Journal of Clinical Oncology* 39: 847-849, 2009.
 - 68) Nakao K, Makino H, Morita S, Takahashi Y, Akizawa T, Saito A, Asano Y, Kurokawa K, Fukuhara S, Akiba T; J-DOPPS Investigators Group: Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study. *Nephron Clinical Practice* 113: c132-139, 2009.

- 69) Ohsumi S, Shimosuma K, Morita S, Hara F, Takabatake D, Takashima S, Taira N, Aogi K, Takashima S: Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. *Japanese Journal of Clinical Oncology* 39: 491-496, 2009.
- 70) Shimokawa T, Kasegawa H, Matsuyama S, Seki H, Manabe S, Fukui T, Morita S, Takanashi S: Long-term outcome of mitral valve repair for infective endocarditis. *The Annals of thoracic surgery* 88: 733-739, 2009.
- 71) Kosuge M, Ebina T, Hibi K, Morita S, Komura N, Hashiba K, Kiyokuni M, Nakayama N, Umemura S, Kimura K: Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. *Circulation Journal* 73: 1105-1110, 2009.
- 72) Shingu Y, Shiiya N, Ooka T, Tachibana T, Kubota S, Morita S, Matsui Y: Augmentation index is elevated in aortic aneurysm and dissection. *The Annals of Thoracic Surgery* 87: 1373-1377, 2009.
- 73) Ohno S, Kyo S, Myojo S, Dohi S, Ishizaka J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H, Inoue M: Wilms' Tumor 1 (WT1) Peptide Immunotherapy for Gynecological Malignancy. *Anticancer Research* 29: 4779-4784, 2009.
- 74) Luo W, Numata K, Morimoto M, Kondo M, Takebayashi S, Okada M, Morita S, Tanaka K: Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. *Radiology* 251: 287-295, 2009.
- 75) Kosuge M, Ishikawa T, Morita S, Ebina T, Hibi K, Maejima N, Umemura S, Kimura K: Posterior wall involvement attenuates predictive value of ST-segment elevation in lead V4R for right ventricular involvement in inferior acute myocardial infarction. *Journal of Cardiology* 54: 386-393, 2009.
- 76) Kato K, Yamada S, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, Kodera Y, Morita S, Nakao A: Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival. *Pancreas* 38: 605-612, 2009.
- 77) Nakagawa M, Kawanishi C, Yamada T, Iwamoto Y, Sato R, Hasegawa H, Morita S, Odawara T, Hirayasu Y: Characteristics of suicide attempters with family history of suicide attempt: a retrospective chart review. *BMC Psychiatry* 9: 32, 2009.
- 78) Nakata B, Tsuji A, Mitachi Y, Taenaka N, Kamano T, Oikawa K, Onoda N, Kambe M, Takahashi M, Shirasaka T, Morita S, Sakamoto J, Tanaka Y, Saji S, Hirakawa K. Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2). *Oncology* 79: 337-42, 2010.
- 79) Ota I, Sakurai A, Toyoda Y, Morita S, Sasaki T, Chishima T, Yamakado M, Kawai Y, Ishidao

- T, Lezhava A, Yoshiura K, Togo S, Hayashizaki Y, Ishikawa T, Ishikawa T, Endo I, Shimada H: Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11. *Anticancer Res* 30: 5189-5194, 2010.
- 80) Nozaki A, Numata K, Morimoto M, Kondo M, Sugimori K, Morita S, Miyajima E, Ikeda M, Kato N, Maeda S, Tanaka K: Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients. *Antivir Ther* 15: 1179-1183, 2010.
- 81) Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K: Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. *J Clin Oncol* 28: 5240-5246, 2010.
- 82) Kodera Y, Fujiwara M, Ohashi N, Nakayama G, Koike M, Morita S, Nakao A: Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials. *J Am Coll Surg* 211: 677-686, 2010.
- 83) Ueda Y, Yamagishi H, Ichikawa D, Okamoto K, Otsuji E, Morii J, Koizumi K, Kakihara N, Shimotsuma M, Yamashita T, Taniguchi F, Aragane H, Nishi H, Itokawa Y, Morita S, Sakamoto J: Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer. *Gastric Cancer* 13: 149-154, 2010.
- 84) Inoue M, Morita S, Watanabe Y, Kaneko T, Yamane S, Kobayashi S, Arakawa A, Kadonosono K: Inner segment/outer segment junction assessed by spectral-domain optical coherence tomography in patients with idiopathic epiretinal membrane. *Am J Ophthalmol* 150: 834-839, 2010.
- 85) Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). *Lancet Oncol* 11: 853-860, 2010.
- 86) Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K: Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. *Cancer* 116: 5452-5460, 2010.
- 87) Morita S, Thall PF, Müller P: Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. *Stat Biosci* 2: 1-17, 2010.
- 88) Miyashita G, Higuchi T, Oriuchi N, Arisaka Y, Hanaoka H, Tominaga H, Morita S, Miyakubo M, Ishikita T, Nakasone Y, Negishi A, Yokoo S, Endo K: ¹⁸F-FAMT uptake correlates with

- tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry. *Ann Nucl Med* 24: 579-584, 2010.
- 89) Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, Takahashi M, Morita S, Sakamoto J, Tanaka T, Kawase I, Hosen N, Sugiyama H: WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. *Eur J Haematol* 85: 358-360, 2010.
 - 90) Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 362: 2380-2388, 2010.
 - 91) Tateishi U, Morita S, Taguri M, Shizukuishi K, Minamimoto R, Kawaguchi M, Murano T, Terauchi T, Inoue T, Kim EE: A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. *Ann Nucl Med* 24: 523-531, 2010.
 - 92) Kobayashi M, Hirawa N, Morita S, Yatsu K, Kobayashi Y, Yamamoto Y, Saka S, Toya Y, Yasuda G, Umemura S: Silent brain infarction and rapid decline of kidney function in patients with CKD: a prospective cohort study. *Am J Kidney Dis* 56: 468-476, 2010.
 - 93) Kosuge M, Ebina T, Hibi K, Morita S, Okuda J, Iwahashi N, Tsukahara K, Nakachi T, Kiyokuni M, Ishikawa T, Umemura S, Kimura K: Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction. *J Am Coll Cardiol* 55: 2514-2516, 2010.
 - 94) Luo W, Numata K, Morimoto M, Nozaki A, Ueda M, Kondo M, Morita S, Tanaka K: Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies. *World J Gastroenterol* 16: 2109-2119, 2010.
 - 95) Fujii T, Kato K, Kodera Y, Kanda M, Nagai S, Yamada S, Kanzaki A, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakamura S, Nakao A: Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. *Surgery* 148: 285-290, 2010.
 - 96) Tsushima K, Sone S, Fujimoto K, Kubo K, Morita S, Takegami M, Fukuhara S: Identification of occult parenchymal disease such as emphysema or airway disease using screening computed tomography. *COPD* 7: 117-125, 2010.
 - 97) Manabe S, Fukui T, Tabata M, Shimokawa T, Morita S, Takanashi S: Arterial graft deterioration one year after coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 140: 1306-1311, 2010.
 - 98) Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, Miyashita Y, Sakamoto J: A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1

- plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). *Jpn J Clin Oncol* 40: 369-372, 2010.
- 99) Ishikawa T, Shimizu D, Sasaki T, Morita S, Tanabe M, Ota I, Kawachi K, Nozawa A, Chishima T, Ichikawa Y, Endo I, Shimada H: A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer. *Jpn J Clin Oncol* 40: 620-626, 2010.
- 100) Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa S, Kaneko T, Miyajima E, Morita S, Mori K, Ikeda M, Kato N, Tanaka K: Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. *Arch Virol* 155: 601-605, 2010.
- 101) Fukui T, Tabata M, Manabe S, Shimokawa T, Shimizu J, Morita S, Takanashi S: Off-pump bilateral internal thoracic artery grafting in patients with left main disease. *J Thorac Cardiovasc Surg* 140: 1040-1045, 2010.
- 102) Toi M, Sperinde J, Huang W, Saji S, Winslow J, Jin X, Tan Y, Ohno S, Nakamura S, Iwata H, Masuda N, Aogi K, Morita S, Petropoulos C, Bates M: Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. *BMC Cancer* 10: 56, 2010.
- 103) Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, Okuda J, Iwahashi N, Maejima N, Nakachi T, Ohtsuka F, Hashiba K, Tahara Y, Sugano T, Umemura S: Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. *Circ J* 74: 679-685, 2010.
- 104) Manabe S, Fukui T, Shimokawa T, Tabata M, Katayama Y, Morita S, Takanashi S: Increased graft occlusion or string sign in composite arterial grafting for mildly stenosed target vessels. *Ann Thorac Surg* 89: 683-687, 2010.
- 105) Kanda M, Fujii T, Sahin TT, Kanzaki A, Nagai S, Yamada S, Sugimoto H, Nomoto S, Takeda S, Kodera Y, Morita S, Nakao A: Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. *Ann Surg* 251: 483-487, 2010.
- 106) Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol*,11: 121-128, 2010.
- 107) Heng LS, Yatsuya H, Morita S, Sakamoto J: Vaginal douching in Cambodian women: its prevalence and association with vaginal candidiasis. *J Epidemiol* 20: 70-76, 2010.

- 108) Hirakata H, Tsubakihara Y, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, Saito A, Akiba T, Inaguma D, Fukuhara S, Morita S, Hiroe M, Hada Y, Suzuki M, Akaishi M, Aonuma K, Akizawa T: Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. *Clin Exp Nephrol* 14: 28-35, 2010.
- 109) Fukui T, Tabata M, Manabe S, Shimokawa T, Morita S, Takanashi S: Angiographic outcomes of right internal thoracic artery grafts in situ or as free grafts in coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 139: 868-873, 2010.
- 110) Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K, Nagai Y, Moriyama G, Miyazawa H, Ikebuchi K, Morita S, Kobayashi K, Hagiwara K: Frequency of and variables associated with the EGFR mutation and its subtypes. *Int J Cancer* 126: 651-655, 2010.
- 111) Mathew P, Wen S, Morita S, Thall P. Placental Growth Factor and Soluble c-Kit Receptor Dynamics Characterize the Cytokine Signature of Imatinib in Prostate Cancer and Bone Metastases. *J Interferon Cytokine Res* 31: 539-544, 2011.
- 112) Mitsuhashi T, Hibi K, Kosuge M, Morita S, Komura N, Kusama I, Otsuka F, Endo M, Iwahashi N, Okuda J, Tsukahara K, Ebina T, Umemura S, Kimura K. Relation between hyperinsulinemia and nonculprit plaque characteristics in nondiabetic patients with acute coronary syndromes. *JACC Cardiovasc Imaging* 4: 392-401, 2011.
- 113) Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. *Pancreatology* 11: 68-75, 2011.
- 114) Nakayama T, Morita S, Takashima T, Kamigaki S, Yoshidome K, Ito T, Taguchi T, Sakamoto J, Noguchi S. Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. *Anticancer Res* 31: 3035-3039, 2011.
- 115) Morita S. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West. *Stat Med* 30: 2090-7, 2011.
- 116) Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin TT, Hayashi M, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Pattern of lymph node metastasis spread in pancreatic cancer. *Pancreas* 40: 951-5, 2011.
- 117) Ogino I, Kaneko T, Suzuki R, Matsui T, Takebayashi S, Inoue T, Morita S. Rectal content and intrafractional prostate gland motion assessed by magnetic resonance imaging. *J Radiat Res (Tokyo)* 52: 199-207, 2011.
- 118) Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, Iwahashi N, Endo M, Maejima N, Sugano T, Umemura S. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. *J Cardiol* 57: 275-82, 2011.

- 119) Sakuma Y, Ishitoya J, Komatsu M, Shiono O, Hirama M, Yamashita Y, Kaneko T, Morita S, Tsukuda M. New clinical diagnostic criteria for eosinophilic chronic rhinosinusitis. *Auris Nasus Larynx* 38: 583-8, 2011.
- 120) Yamakawa T, Kaneko T, Shigematu E, Kawaguchi J, Kadonosono K, Morita S, Terauchi Y. Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. *Endocr J* 58: 185-91, 2011.
- 121) Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, Kobayashi S, Ohkawa S, Okuse C, Morita S, Taguri M, Tanaka K. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. *Hepatol Res* 41: 296-302, 2011.
- 122) Imamoto H, Oba K, Sakamoto J, Iishi H, Narahara H, Yumiba T, Morimoto T, Nakamura M, Oriuchi N, Kakutani C, Morita S, Shiozaki H. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. *Gastric Cancer* 14: 81-90, 2011.
- 123) Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Hayashi M, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistula. *Ann Surg Oncol* 18: 2329-37, 2011.
- 124) Morizane C, Okusaka T, Morita S, Tanaka K, Ueno H, Kondo S, Ikeda M, Nakachi K, Mitsunaga S. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. *Pancreas* 40: 415-21, 2011.
- 125) Fukui T, Tabata M, Taguri M, Manabe S, Morita S, Takanashi S. Extensive reconstruction of the left anterior descending coronary artery with an internal thoracic artery graft. *Ann Thorac Surg* 91: 445-51, 2011.
- 126) Inoue M, Morita S, Watanabe Y, Kaneko T, Yamane S, Kobayashi S, Arakawa A, Kadonosono K. Preoperative inner segment/outer segment junction in spectral-domain optical coherence tomography as a prognostic factor in epiretinal membrane surgery. *Retina* 31: 1366-72, 2011.
- 127) Yanagimachi M, Naruto T, Hara T, Kikuchi M, Hara R, Miyamae T, Imagawa T, Mori M, Kaneko T, Morita S, Goto H, Yokota S. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. *Br J Clin Pharmacol* 71: 237-43, 2011.
- 128) Kosuge M, Ebina T, Hibi K, Morita S, Endo M, Maejima N, Iwahashi N, Okada K, Ishikawa T, Umemura S, Kimura K. An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. *Am J Cardiol* 107: 495-500, 2011.

- 129) Yanagimachi M, Miyamae T, Naruto T, Hara T, Kikuchi M, Hara R, Imagawa T, Mori M, Kaneko T, Goto H, Morita S, Mizuki N, Kimura A, Yokota S. Association of HLA-A*02:06 and HLA-DRB1*04:05 with clinical subtypes of juvenile idiopathic arthritis. *J Hum Genet* 56: 196-9, 2011.
- 130) Kunisaki C, Makino H, Oshima T, Fujii S, Kimura J, Takagawa R, Kosaka T, Akiyama H, Morita S, Endo I. Application of the transorally inserted anvil (OrVil) after laparoscopy-assisted total gastrectomy. *Surg Endosc* 25: 1300-5, 2011.
- 131) Nakagawa M, Kawanishi C, Yamada T, Sugiura K, Iwamoto Y, Sato R, Morita S, Odawara T, Hirayasu Y. Comparison of characteristics of suicide attempters with schizophrenia spectrum disorders and those with mood disorders in Japan. *Psychiatry Res* 188: 78-82, 2011.
- 132) Kodera Y, Imano M, Yoshikawa T, Takahashi N, Tsuburaya A, Miyashita Y, Morita S, Nakao A, Sakamoto J, Sasako M. A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). *Jpn J Clin Oncol* 41: 283-6, 2011.
- 133) Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. *Pancreas* 40: 3-9, 2011.
- 134) Kunisaki C, Takahashi M, Makino H, Oshima T, Fujii S, Takagawa R, Kimura J, Kosaka T, Ono HA, Akiyama H, Kameda K, Kito F, Morita S, Endo I. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer. *Cancer Chemother Pharmacol* 67: 1363-8, 2011.
- 135) Shakudo M, Takegami M, Shibata A, Kuzumaki M, Higashi T, Hayashino Y, Suzukamo Y, Morita S, Katsuki M, Fukuhara S. Effect of feedback in promoting adherence to an exercise programme: a randomized controlled trial. *J Eval Clin Pract* 17: 7-11, 2011.
- 136) Hirama T, Yamaguchi T, Miyazawa H, Tanaka T, Hashikita G, Kishi E, Tachi Y, Takahashi S, Kodama K, Egashira H, Yokote A, Kobayashi K, Nagata M, Ishii T, Nemoto M, Tanaka M, Fukunaga K, Morita S, Kanazawa M, Hagiwara K. Prediction of the pathogens that are the cause of pneumonia by the battlefield hypothesis. *PLoS ONE* 6: 1-11, 2011.
- 137) Kawaguchi K, Ishiguro H, Morita S, Nakamura S, Ohno S, Masuda N, Iwata H, Aogi K, Kuroi K, Toi M. Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey. *Breast Cancer Res Treat.* 130: 627-34, 2011.
- 138) Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F, Ishiguro H, Nakaigawa N, Nagashima Y, Taguri M, Kubota Y, Goshima Y, Morita S, Endo I, Maeda S, Nakajima A, Nakagama H. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. *Cancer Sci.* 102: 2029-37, 2011.

- 139) Fujii T, Kanda M, Kodera Y, Nagai S, Sahin TT, Hayashi M, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Preservation of the Pyloric Ring Has Little Value in Surgery for Pancreatic Head Cancer: A Comparative Study Comparing Three Surgical Procedures. *Ann Surg Oncol*. 19: 176-83, 2011.
- 140) Sahin TT, Fujii T, Kanda M, Nagai S, Kodera Y, Kanzaki A, Yamamura K, Sugimoto H, Kasuya H, Nomoto S, Takeda S, Morita S, Nakao A. Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas. *Pancreas*. 40: 1029-33, 2011.
- 141) Fujii T, Kanda M, Kodera Y, Nagai S, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Morita S, Takeda S, Nakao A. Comparison of Pancreatic Head Resection With Segmental Duodenectomy and Pylorus-Preserving Pancreatoduodenectomy for Benign and Low-Grade Malignant Neoplasms of the Pancreatic Head. *Pancreas*. 40: 1258-63, 2011.
- 142) Ito M, Kaneko T, Goto H, Yamaguchi N, Fujisawa S, Ono S, Morita S, Miyazawa N, Kanamori H, Watanuki Y, Ishigatsubo Y. Clinical efficacy of carbapenems on hospital-acquired pneumonia in accordance with the Japanese Respiratory Society Guidelines for management of HAP. *J Infect Chemother*. 17: 770-5, 2011.
- 143) Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. *Lung Cancer*. 74: 268-73, 2011.
- 144) Arata S, Suzuki J, Moriwaki Y, Suzuki N, Iwashita M, Sugiyama M, Morita S. Characteristics of high-echoic objects in the hepatic vessels of patients with cardiopulmonary arrest: a prospective cohort study. *Emerg Med J*. 29: 213-218, 2011.
- 145) Hirasawa K, Kokawa A, Oka H, Yahara S, Sasaki T, Nozawa A, Morimoto M, Numata K, Taguri M, Morita S, Maeda S, Tanaka K. Risk assessment chart for curability of early gastric cancer with endoscopic submucosal dissection. *Gastrointestinal Endoscopy* 74: 1268-75, 2011.
- 146) Yanagimachi M, Goto H, Miyamae T, Kadota K, Imagawa T, Mori M, Sato H, Yanagisawa R, Kaneko T, Morita S, Ishii E, Yokota S. Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children. *J Clinical Immunology* 31: 946-51, 2011.
- 147) Kubota M, Hiramatsu M, Yamakawa M, Fukuhara S, Morita S, Iwasaki M, Akizawa T, KRN321 SCA10 Study Group. Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan. *Clin Exp Nephrol* 15: 884-892, 2011.
- 148) Kako S, Morita S, Sakamaki H, Ogawa H, Fukuda T, Takahashi S, Kanamori H, Onizuka M, Iwato K, Suzuki R, Atsuta Y, Kyo T, Sakura T, Jinnai I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y. A decision analysis of allogeneic hematopoietic stem cell

- transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. *Leukemia* 25: 259–265, 2011.
- 149) Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, Saito A, Akiba T, Hirakata H, Fukuhara S, Morita S, Hiroe M, Hada Y, Suzuki M, Akaishi M, Iwasaki M, Tsubakihara Y; KRN321 STUDY Group. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. *Therapeutic Apheresis and Dialysis* 15: 431-40, 2011.
- 150) Kunisaki C, Makino H, Kosaka T, Oshima T, Fujii S, Takagawa R, Kimura J, Ono HA, Akiyama H, Taguri M, Morita S, Endo I. Surgical outcomes of laparoscopy-assisted gastrectomy versus open gastrectomy for gastric cancer: a case-control study. *Surgical Endoscopy* 26: 804-10, 2012.
- 151) Morimoto M, Numata K, Nozaki A, Kondo M, Moriya S, Taguri M, Morita S, Konno M, Sugo A, Miyajima E, Maeda S, Tanaka K. Novel Lens culinaris agglutinin-reactive fraction of α -fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α -fetoprotein concentrations. *Int J Clin Oncol*. 17: 373-379, 2012.
- 152) Kou K, Aihara M, Matsunaga T, Chen H, Taguri M, Morita S, Fujita H, Yamaguchi Y, Kambara T, Ikezawa Z. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. *Arch Dermatol Res*. 304:305-312, 2012.
- 153) Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival and overall survival for chemotherapy of patients with advanced non–small cell lung cancer. *Annals of Oncology* 23: 1537-1541, 2012.
- 154) Shitara K, Morita S, Fujitani K, Kadowaki S, Takiguchi N, Hirabayashi N, Takahashi M, Takagi M, Tokunaga Y, Fukushima R, Munakata Y, Nishikawa K, Takagane A, Tanaka T, Sekishita Y, Kang Y, Sakamoto J, Tsuburaya A. Combination Chemotherapy with S-1 plus Cisplatin for Gastric Cancer that Recurs after Adjuvant Chemotherapy with S-1: Multi-institutional Retrospective Analysis. *Gastric Cancer* 15: 245-251, 2012.
- 155) Yoshikawa T, Morita S, Taguri M, Sakuramoto S, Kunisaki C, Fukunaga T, Ito S, Tsuburaya A. A comparison of multimodality treatment; two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/Docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer, a randomized phase II trial (COMPASS-D trial). *Japanese Journal of Clinical Oncology* 42: 74-7, 2012.
- 156) Fukui T, Tabata M, Morita S, Takanashi S. Sequential free right internal thoracic artery grafting for multivessel coronary artery bypass graft surgery. *J Thorac Cardiovasc Surg* 144: 824-829, 2012.
- 157) Chiba Y, Kinoshita M, Okita Y, Tsuboi A, Isohashi K, Kagawa N, Fujimoto Y, Oji Y, Oka Y,

- Shimosegawa E, Morita S, Hatazawa J, Sugiyama H, Hashimoto N, Yoshimine T. Use of ¹¹C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma. *Journal of Neurosurgery* 116: 835-842, 2012.
- 158) Fujii S, Watanabe K, Ota M, Ichikawa Y, Yamagishi S, Tatsumi K, Suwa H, Kunisaki C, Taguri M, Morita S, Endo I. Single-incision laparoscopic surgery using colon-lifting technique for colorectal cancer: a matched case-control comparison to standard multiport laparoscopic surgery in terms of short-term results and access instrument cost. *Surgical Laparoscopy, Endoscopy & Percutaneous Techniques* 26: 1403-11, 2012.
- 159) Nishikawa K, Morita S, Matsui T, Miyashita Y, Tsuburaya A, Sakamoto J, Kakeji Y, Baba H. A randomised phase-II trial comparing sequential and concurrent Paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. *Gastric Cancer* 15: 363-369, 2012.
- 160) Morita S, Thall PF, and Mueller P. Prior effective sample size in conditionally independent hierarchical models. *Bayesian Analysis*. 7: 591-614, 2012.
- 161) Yoshikawa T, Hiki N, Taguri M, Sano T, Nunobe S, Taniguchi H, Fukushima R, Cho H, Morita S, Tsuburaya A. A Phase III trial to evaluate the effect of perioperative nutrition enriched with eicosapentaenoic acid on body weight loss after total gastrectomy for T2-T4a gastric cancer. *Jpn J Clin Oncol*. 42: 459-62, 2012.
- 162) Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, Kawai H, Kato S, Suenaga M, Tamura F, Morita S, Boku N. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. *The Oncologist*. 17: 1163-1170, 2012.
- 163) Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH. Taxane-induced peripheral neuropathy and health-related quality-of-life in post-operative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. *Supportive Care in Cancer*. 20: 3355-3364, 2012.
- 164) Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, and Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-mutated Non-small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *The Oncologist*. 17: 863-70, 2012.
- 165) Yoshikawa T, Fukunaga T, Taguri M, Kunisaki C, Sakuramoto S, Ito S, Morita S, Tsuburaya A. Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for operable gastric cancer, a randomized phase II trial (LANDSCOPE trial). *Jpn J Clin Oncol* 42: 654-657, 2012.

- 166) Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, Sakai E, Uchiyama T, Hata Y, Uchiyama S, Kawana K, Nagase H, Morita S, Natsumeda Y, Nakajima A. Metformin efficacy and safety for colorectal polyps: A double blind randomized controlled trial. *BMC Cancer*. 12: 118, 2012.
- 167) Sugihara M, Morita S, Yamanouchi N, Sakai S, Ohba N, Ichikawa W, Ohashi Y. Dynamic registration method with balancing for prognostic factors in observational studies. *Journal of Biometrics & Biostatistics*. 2012 [Epub ahead of print]
- 168) Tsuburaya A, Morita S, Kodera Y, Kobayashi M, Shitara K, Yamaguchi K, Yoshikawa T, Yoshida K, Yoshino S, Sakamoto J. A randomized phase II trial to elucidate the efficacy of XP and SP as the first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII (XParTS II) trial. *BMC Cancer*. *BMC Cancer*. 12: 307, 2012.
- 169) Kumagai K, Sakai K, Kusayama Y, Akamatsu Y, Sakamaki K, Morita S, Sasaki T, Saito T, Sakai T. The extent of degeneration of cruciate ligament is associated with chondrogenic differentiation in patients with osteoarthritis of the knee. *Osteoarthritis and Cartilage* 20: 1258-1267, 2012.
- 170) Fujii S, Watanabe K, Ota M, Watanabe J, Ichikawa Y, Yamagishi S, Tatsumi K, Suwa H, Kunisaki C, Taguri M, Morita S, Endo I. Laparoscopic colorectal cancer surgery by a colon lifting-up technique that decreases the number of access ports: comparison by propensity scoring of short-term and long-term outcomes with standard multiport laparoscopic surgery. *Surg Laparosc Endosc Percutan Tech*. 22: 38-45, 2012.
- 171) Kumagai K, Sakai K, Kusayama Y, Akamatsu Y, Sakamaki K, Morita S, Sasaki T, Saito T, Sakai T. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. *Neurology*. 78:803-10, 2012.
- 172) Fukuhara S, Akizawa T, Morita S, Tsubakihara Y. Understanding Measurements of Vitality in Patients with Chronic Kidney Disease: Connecting a Quality-of-Life Scale to Daily Activities. *PLOS ONE* 7: e40455, 2012.
- 173) Yoshimoto M, Takao S, Hirata M, Okamoto Y, Yamashita S, Kawaguchi Y, Takami M, Furusawa H, Morita S, Abe C, Sakamoto J. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. *Cancer Chemother Pharmacol*. 70: 331-338, 2012.
- 174) Ishikawa T, Shimizu D, Yamada A, Sasaki T, Morita S, Tanabe M, Kawachi K, Nozawa A, Chishima T, Kimura M, Ichikawa Y, Endo I. Impacts and predictors of cytotoxic anticancer agents in different breast cancer subtypes. *Oncol Res*. 20: 71-79, 2012.
- 175) Miyatake S, Touho H, Miyake N, Ohba C, Doi H, Saitsu H, Taguri M, Morita S, Matsumoto N. Sibling cases of moyamoya disease having homozygous and heterozygous c.14576G>A variant in RNF213 showed varying clinical course and severity. *Journal of Human Genetics*

57: 804-6, 2012.

- 176) Yano H, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K. Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes: A prospective, randomized, multi-center study. *Circulation Journal* 76: 2673-2680, 2012.
- 177) Miyahara T, Mochinaga S, Kimura S, Aragane N, Yakabe T, Morita S, Okudaira T, Fujito H. Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients. *Cancer Chemotherapy and Pharmacology* 71:175–182, 2012.
- 178) Kosuge M, Ebina T, Hibi K, Iwahashi N, Tsukahara K, Endo M, Maejima N, Nagashima Z, Suzuki H, Morita S, Umemura S, Kimura K. Differences in negative T waves among acute coronary syndrome, acute pulmonary embolism, and takotsubo cardiomyopathy *European Heart Journal: Acute Cardiovascular Care* 4:349-357,2012.
- 179) Nagakura H, Nishikawa M, Kusano N, Saito M, Morita S, Kaneko T, Ishigatsubo Y. The impact of a negative history of smoking on survival in patients with non-small cell lung cancer detected with clinic-based screening programs. *Intern Med.* 51: 3115-8, 2012.
- 180) Yamamura K, Nakao A, Fujii T, Yamada S, Sugimoto H, Kasuya H, Nomoto S, Kodera Y, Nakamura S, Morita S, Takeda S. Clinicopathologic study of intrapancreatic cancer spread in carcinoma of the body and tail of the pancreas. *Pancreas.* 41: 753-758, 2012.
- 181) Kosuge M, Ebina T, Hibi K, Iwahashi N, Tsukahara K, Endo M, Maejima N, Nagashima Z, 2012Suzuki H, Morita S, Umemura S Kimura K. Differences in Negative T Waves Between Takotsubo Cardiomyopathy and Reperfused Anterior Acute Myocardial Infarction. *Circulation Journal.* 76: 462-468, 2012.
- 182) Yano H, Hibi K, Nozawa N, Ozaki H, Kusama I, Ebina T, Kosuge M, Tsukahara K, Okuda J, Morita S, Umemura S, Kimura K. Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction Who Receive an Angiotensin-Converting-Enzyme Inhibitor. *Circulation Journal.* 76: 1442-1451,2012.
- 183) Fujii S, Watanabe K, Ota M, Watanabe J, Ichikawa Y, Yamagishi S, Tatsuimi K, Suwa H, Kunisaki C, Taguri M, Morita S, Endo I. Single-incision laparoscopic surgery using colon-lifting technique for colorectal cancer: a matched case-control comparison with standard multiport laparoscopic surgery in terms of short-term results and access instrument cost. *Surgical Endoscopy.* 26: 1403-1411,2012.
- 184) Higurashi T, Hosono K, Endo H, Takahashi H, Iida H, Uchiyama T, Ezuka A, Uchiyama S, Yamada E, Ohkubo H, Sakai E, Maeda S, Morita S, Natsumeda Y, Nagase H, Nakajima A. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF) : A double-blind randomized controlled trial. *BMC Cancer.* 12:413,2012.

- 185) Hasegawa S, Kunisaki C, Ono H, Oshima T, Fujii S, Taguri M, Morita S, Sato T, Yamada R, Yukawa N, Rino Y, Masuda M. Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study. *Gastric Cancer*. 16: 383-388, 2013.
- 186) Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. *Int J Clin Oncol* 18: 335-342, 2013.
- 187) Fukui T, Tabata M, Morita S, Takanashi S, Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. *J Thorac Cardiovasc Surg*, 145: 1577-1583, 2013.
- 188) Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. for the North-East Japan Study Group. Updated Overall Survival Results from A Randomized Phase III Trial Comparing Gefitinib with Carboplatin-Paclitaxel for Chemo-Naïve Non-Small Cell Lung Cancer with Sensitive EGFR Gene Mutations (NEJ002). *Annals of Oncology* 24: 54-59, 2013.
- 189) Horita N, Miyazawa N, Yoshiyama T, Sato T, Yamamoto M, Tomaru K, Masuda M, Tashiro K, Sasaki M, Morita S, Kaneko T, Ishigatsubo Y. Development and validation of a tuberculosis prognostic score for smear positive inpatients. *International Journal of Tuberculosis and Lung Disease* 17: 54-60, 2013
- 190) Morimoto M, Numata K, Kondo M, Moriya S, Morita S, Maeda S, Tanaka K. Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: A prospective cohort study. *European Journal of Radiology*. 82:497-503, 2013.
- 191) Hayashi T, Yoshikawa T, Bonam K, Taguri M, Morita S, Hyden J, Grabsh H. The superiority of the TNM classification depends of the overall survival rate of the patient cohort - comparative analysis of the 6th and 7th editions in patients with gastric cancer from Japan and United Kingdom. *Cancer* 119: 1330-1337, 2013.
- 192) Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H, Kimura T. WT1 Peptide Immunotherapy for Gynecologic Malignancies Resistant to Conventional Therapies: a Phase II trial. *J Cancer Res Clin Oncol*. 139: 457-463, 2013.
- 193) Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K. Efficacy and safety analysis by histology of S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer: Updated results

- of a West Japan Oncology Group LETS study. *Annals of Oncology* 24: 1326-31, 2013.
- 194) Wasada I, Eguchi H, Kurita M, Kudo S, Shishida T, Mishima Y, Saito Y, Ushiorozawa N, Seto T, Shimozuma K, Morita S, Saito M, Yokomizo Y, Ishizawa K, Ohashi Y, Eguchi K. Anemia affects quality of life among Japanese cancer patients. *Tokai J Exp Clin Med.*, 38: 7-11, 2013.
- 195) Hasegawa S, Yamamoto Y, Taguri M, Morita S, Sato T, Yamada R, Oshima T, Yukawa N, Yoshikawa T, Rino Y, Imada T, Masuda M. A randomized phase II trial of omentum-preserving gastrectomy for advanced gastric cancer. *Jpn J Clin Oncol* 43:214–216, 2013.
- 196) Shimoyama Y, Nozaki A, Morimoto M, Moriya S, Kondo M, Fukuda H, Numata K, Miyajima E, OBA M, Taguri M, Morita S, Maeda S, Tanaka K. Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C. *Hepatology Research* .43:919-924, 2013.
- 197) Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Chishima T, Sasaki T, Ichikawa Y, Morita S, Yoshimura K, Takabe K, Endo I. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. *Breast Cancer Research and Treatment* 137:773-782, 2013.
- 198) Kako S, Morita S, Sakamaki S, Iida H, Kurokawa M, Miyamura K, Kanamori H, Hara M, Kobayashi N, Morishima Y, Kawa K, Kyo T, Sakura T, Jinnai I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y. The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis. *Bone Marrow Transplantation*. 48:1077-1083, 2013.
- 199) Takeda A, Sanuki N, Eriguchi T, Kaneko T, Morita S, Handa H, Aoki Y, Oku Y, Kunieda E. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* .86:257-263, 2013.
- 200) Okada K, Kawai M, Uesaka K, Kodera Y, Nagano H, Murakami Y, Morita S, Sakamoto J, Yamaue H. Effect of Daikenchuto (TJ-100) on postoperative bowel motility and on prevention of paralytic ileus after pancreaticoduodenectomy: a multicenter, randomized, placebo-controlled phase II trial (the JAPAN-PD study). *Jpn J Clin Oncol*.43:436-438, 2013.
- 201) Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. *Clin Lung Cancer* 14: 261-266, 2013.
- 202) Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell

- lung cancer. *Cancer*. 119: 2275-81, 2013.
- 203) Sakane N, Kotani K, Takahashi K, Sano Y, Tsuzaki K, Okazaki K, Sato J, Suzuki S, Morita S, Izumi K, Kato M, Ishizuka N, Noda M, Kuzuya H. Japan Diabetes Outcome Intervention Trial-1(J-DOIT1), a nationwide trial of type 2 diabetes prevention by telephone-delivered lifestyle support for high-risk subjects detected at health checkups: Rationale, design, and recruitment. *BMC Public Health* 13:81, 2013.
- 204) Matsuzawa Y, Konishi M, Akiyama E, Suzuki H, Nakayama N, Kiyokuni M, Sumita S, Ebina T, Kosuge M, Hibi K, Tsukahara K, Iwahashi N, Endo M, Maejima N, Saka K, Hashiba K, Okada K, Taguri M, Morita S, Sugiyama S, Ogawa H, Sashika H, Umemura S, Kimura K. Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction. *J Am Coll Cardiol* 61: 1964-1972, 2013.
- 205) The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. *European Journal of Cancer* .49:1565-1577, 2013.
- 206) Konishi M, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Matsubara J, Sakamoto K, Nagayoshi Y, Sumida H, Akiyama E, Matsuzawa Y, Sakamaki K, Morita S, Kimura K, Umemura S, Ogawa H. Basal and Ischemia-Induced Transcardiac Troponin Release into the Coronary Circulation in Patients with Suspected Coronary Artery Disease. *PLOS ONE* 8: e60163, 2013.
- 207) Shiozawa T, Tadokoro J, Fujiki T, Fujino K, Kakihata K, Masatani S, Morita S, Gemma A, Boku N. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. *Jpn J Clin Oncol* 43:483-491, 2013.
- 208) Imoto K, Uchida K, Karube N, Yasutsune T, Cho T, Kimura K, Masuda M, Morita S. Risk analysis and improvement of strategies in patients who have acute type A aortic dissection with coronary artery dissection. *Eur J Cardiothorac Surg* .44:419-424, 2013.
- 209) Takahiro Mihara, Tojo K, Uchimoto K, Morita S, Goto T. Yokohama city university Reevaluation of the effectiveness of ramosetron in preventing post-operative nausea and vomiting: a systematic review and meta-analysis. *Anesthesia & Analgesia*.117:329-339, 2013.
- 210) Horita N, Miyazawa N, Morita S, Kojima R, Kimura N, Kaneko T, Ishigatsubo Y. Preoperative Chemotherapy is Effective for Stage III Resectable Non-Small Cell Lung Carcinoma: Meta-Analysis of 16 Trials. *Clin Lung Cancer* .14:488-494, 2013.
- 211) Asano F, Shinagawa N, Ishida T, Shindoh J, Anzai M, Akifumi T, Oizumi S, Morita S. Virtual bronchoscopic navigation combined with ultrathin bronchoscopy. A randomized clinical trial. *Am J Respir Crit Care Med*. 188: 327-333, 2013.

- 212) Yamamoto Y, Tasaki Y, Kuwada Y, Ozawa Y, Katayama A, Kanemaki Y, Enokido K, Nakamura S, Kubouchi K, Morita S, Noritake M, Nakajima Y, Inoue T. Positron emission mammography (PEM): reviewing standardized semiquantitative method. *Ann Nucl Med* .27:795-801, 2013.
- 213) Kawahara T, Morita S, Ito H, Terao H, Sakata R, Ishiguro H, Tanaka K, Miyamoto H, Matsuzaki J, Kubota Y, Uemura H. Ramelteon combined with an alpha1-blocker might decrease nocturia in men with benign prostatic hyperplasia. *BMC Urology*. 13: 30, 2013.
- 214) Horita N, Kaneko T, Shinkai M, Yomota M, Morita S, Rubin BK, Ishigatsubo Y. Depression in Japanese patients with chronic obstructive pulmonary disease: a cross-sectional study. *Respir Care*. 58: 1196-203, 2013.
- 215) Matsuzawa Y, Sugiyama S, Sumida H, Sugamura K, Nozaki T, Ohba K, Matsubara J, Kurokawa H, Fujisue K, Konishi M, Akiyama E, Suzuki H, Nagayoshi Y, Yamamuro M, Sakamoto K, Iwashita S, Jinnouchi H, Taguri M, Morita S, Matsui K, Kimura K, Umemura S, Ogawa H. Peripheral endothelial function and cardiovascular events in high-risk patients. *J Am Heart Assoc*. 2: e000426, 2013.
- 216) Horita N, Miyazawa N, Morita S, Kojima R, Kimura N, Kaneko T, Ishigatsubo Y. Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study. *Respir Res*. 14:62, 2013.
- 217) Paoletti X, Oba K, Bang YJ, Bleiberg H, Boku N, Bouché O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, Ohtsu A, Roth A, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Thuss-Patience P, Cutsem EV, Burzykowski T, Buyse M; on behalf of the GASTRIC group. Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. *J Natl Cancer Inst*.105:1667-1670, 2013.
- 218) Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T; on behalf of the GASTRIC group. Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. *J Natl Cancer Inst* .105:1600-1607, 2013.
- 219) Koyama Y, Andoh Y, Kamiya Y, Morita S, Miyazaki T, Uchimoto K, Mihara T, Goto T. Bumetanide, an Inhibitor of Cation-Chloride Co-Transporter Isoform 1, Inhibits GABAergic Excitatory Actions and Enhances Sedative Actions of Midazolam in Neonatal Rats. *Anesthesiology* .119:1096-1108, 2013.
- 220) Kawakami H, Okamoto I, Hayashi H, Taguri M, Morita S, Nakagawa K. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. *Eur J Cancer*. 49:3003-3009, 2013.

- 221) Kitagawa Y, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Tsujimoto H, Hayashi H, Yoshimizu N, Takagane A, Mohri Y, Nabeshima K, Uenosono Y, Kinami S, Sakamoto J, Morita S, Aikou T, Miwa K, Kitajima M. Sentinel node mapping for gastric cancer: A prospective multicenter trial in Japan. *J Clin Oncol* .31:3704-3710, 2013.
- 222) Nishino K, Imamura F, Morita S, Mori M, Komuta K, Kijima T, Namba Y, Kumagai T, Yamamoto S, Tachibana I, Nakazawa Y, Uchida J, Minami S, Takahashi T, Yano Y, Okuyama T, Kumanogoh A. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. *Lung Cancer* .82:299-304, 2013.
- 223) Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, Minami H, Katakami N, Morita S, Negoro S. A randomized, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. *British Journal of Cancer* .109:859-865, 2013.
- 224) Okano Y, Nezu U, Kinoshita H, Miyagi Y, Nakayama H, Yokose T, Morita S, Taguri M, Lezhava A, Ichikawa Y, Kaneko T, Natsumeda Y, Hayashizaki Y, Ishikawa T. SNP (-617G>A) in ARE-like loci of the NRF2 gene: A new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women. *PROS ONE* .8:e73794, 2013.
- 225) Hironaka S, Ueda S, Yasui H, Nishina H, Tsuda M, Tsumura T, Sugimoto T, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol*.31:4438-4444, 2013.
- 226) Hattori Y, Satouchi M, Kotani Y, Iwasaku M, Yoshioka H, Nishiyama A, Korogi Y, Shimada T, Urata Y, Katakami N, Fujita S, Otsuka K, Monden K, Mori M, Nishino K, Morita S, Negoro S. A Phase II Study of Pemetrexed in Chemotherapy-Naïve Elderly Patients Aged 75 Years or Older with Advanced Non-Squamous Non-Small-Cell Lung Cancer (HANSHIN Oncology Group 003). *Jpn J Clin Oncol* 43: 1184–1189, 2013.
- 227) Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin - induced neuropathy. *Cancer Chemother Pharmacol* 72: 1283-1290, 2013.
- 228) Yamada Y. Takahari D. Matsumoto H. Baba H. Nakamura M. Yoshida K. Yoshida M. Iwamoto S. Shimada K. Komatsu Y. Sasaki Y. Satoh T. Takahashi T. Mishima H. Muro K. Watanabe M. Sakata Y. Morita S. Shimada Y. Sugihara K. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an

- open-label, non-inferiority, randomized phase 3 trial. *Lancet Oncol* 13: 1278-1286, 2013.
- 229) Koh R, Hirasawa K, Yahara S, Oka H, Sugimori K, Morimoto M, Numata K, Kokawa A, Sasaki T, Nozawa A, Taguri M, Morita S, Maeda S, Tanaka K. Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. *Gastrointest Endosc* 78: 476-483, 2013.
- 230) Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K. reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. *J Cardiology*. 62:158-164,2013.
- 231) Kanda Y, Kanda J, Atsuta Y, Maeda Y, Ichinohe T, Ohashi K, Fukuda T, Miyamura K, Iida H, Mori T, Iwato K, Eto T, Kawa K, Morita S, Morishima Y. Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation. *Br J Haematol*. 161: 566-577, 2013.
- 232) Kikuchi T, Tan H, Mihara T, Uchimoto K, Mitsushima D, Takase K, Morita S, Goto T, Andoh T, Kamiya Y. Effects of volatile anesthetics on the circadian rhythms of rat hippocampal acetylcholine release and locomotor activity. *Neuroscience*. 237:151-160,2013.
- 233) Iwasawa T, Ogura T, Sakai F, Kanauchi T, Komagata T, Baba T, Gotoh T, Morita S, Yazawa T, Inoue T. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. *European Journal of Radiology* 83: 32-38, 2014.
- 234) Yoshikawa T, Tanabe K, Nishikawa K, Ito S, Matsui T, Fujita J, Hirabayashi N, Mikata A, Iwahashi M, Fukushima R, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. *Ann Surg Oncol* .21:213-219, 2014.
- 235) Horita N, Yomota M, Sasaki M, Morita S, Shinkai M, Ishigatsubo Y, Kaneko T. Evaluation of the Chronic Obstructive Pulmonary Disease Assessment Test in Japanese Outpatients. *Clin Respir J*. 8: 213-219, 2014.
- 236) Horita N, Miyazawa N, Morita S, Kojima R, Kimura N, Kaneko T, Ishigatsubo Y. Small, Moderate, and Large Changes, and the Minimum Clinically Important Difference in the University of California, San Diego Shortness of Breath Questionnaire. *COPD*. 11:26-32,2014.
- 237) Misawa K, Mochizuki Y, Ohashi N, Matsui T, Nakayama H, Tsuboi K, Sakai M, Ito S, Morita S, Kodera Y. A Randomized Phase III Trial Exploring the Prognostic Value of Extensive Intraoperative Peritoneal Lavage In Addition to Standard Treatment for Resectable Advanced Gastric Cancer: CCOG 1102 Study. *Jpn J Clin Oncol*. 44:101-103,2014.
- 238) Kakizume T, Morita S. A continual reassessment method with cohort size adaptation based on

- Bayesian posterior probabilities in phase I dose-finding studies. *Therapeutic Innovation & Regulatory Science*. 48: 213-219, 2014.
- 239) Konishi M, Matsuzawa Y, Suzuki H, Akiyama E, Iwahashi N, Maejima N, Endo M, Tsukahara K, Hibi K, Kosuge M, Ebina T, Sakamaki K, Morita S, Umemura S, Kimura K. Higher Level at Admission and Subsequent Decline in Hemoglobin in Patients with Acute Pulmonary Edema. *Circulation Journal*. 78: 896-902, 2014.
- 240) Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Eguchi H, Wada H, Kitagawa T, Nagano H, Hosen N, Oji Y, Tanaka T, Kumanogo A, Sakamoto J, Ito T, Doki Y, Mori M, Ohkusa T, Tajiri H, Sugiyama H. Wilms Tumor Gene (WT1) Peptide-based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer. *Journal of Immunotherapy*. 37:105-114, 2014.
- 241) Hattori Y, Satouchi M, Katakami N, Fujita S, Kaji R, Hata A, Urata Y, Shimada T, Uchida J, Tomii K, Morita S, Negoro S. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001). *Cancer Chemother Pharmacol* 73: 17–23, 2014.
- 242) Yamamoto N, Yamaguchi H, Ohmura K, Yokoyama T, Yoshifuji H, Yukawa N, Kawabata D, Fujii T, Morita S, Nagata S, Mimori T. Serum milk fat globule epidermal growth factor 8 elevation may subdivide systemic lupus erythematosus into two pathophysiologically distinct subsets. *Lupus*. 23: 386-394, 2014.
- 243) Ogura T, Morita S, Yonemori K, Nonaka T, Urano T. Exploring ethnic differences in toxicity in early phase clinical trials for oncology drugs. *Therapeutic Innovation & Regulatory Science*. 48: 644-650, 2014.
- 244) Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). *Breast Cancer Res Treat*. 145: 143-153, 2014.
- 245) Fujikawa H, Yoshikawa T, Hasegawa S, Hayashi T, Aoyama T, Ogata T, Cho H, Oshima T, Rino Y, Masuda M, Morita S, Tsuburaya A. Diagnostic value of computed tomography for staging of clinical T1 gastric cancer. *Annals of Surgical Oncology*. 21: 3002-3007, 2014.
- 246) Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hasegawa S, Aoyama T, Hayashi T, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy - cohort evaluation within the randomized phase II study. *Annals of Surgical Oncology*. 21: S385-S389, 2014.

- 247) Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hasegawa S, Aoyama T, Hayashi T, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy. *Annals of Surgical Oncology*. 21: 3015-3022,2014.
- 248) Numata M Godai T. Shirai J. Watanabe K. Inagaki D. Hasegawa S. Sato T. Oshima T. Fujii S. Kunisaki C. Yukawa N. Rino Y. Taguri M. Morita S. Masuda M. A prospective randomized controlled trial of subcutaneous passive drainage for the prevention of superficial surgical site infections in open and laparoscopic colorectal surgery. *Int J Colorectal* 29: 353-358, 2014
- 249) Cho H, Yoshikawa T, Oba MS, Hirabayashi N, Shirai J, Aoyama T, Hayashi T, Yamada T, Oba K, Morita S, Sakamoto J, Tsuburaya A. Matched pair analysis to examine the effects of a planned preoperative exercise program in early gastric cancer patients with metabolic syndrome to reduce operative risk: the Adjuvant Exercise for General Elective Surgery (AEGES) study group. *Ann Surg Oncol*. 21: 2044-2050, 2014.
- 250) Aoyama T, Yoshikawa T, Morita S, Shirai J, Fujikawa H, Iwasaki K, Hayashi T, Ogata T, Cho H, Yukawa N, Oshima T, Rino Y, Masuda M, Tsuburaya A. Methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective randomized phase III study. *BMC Cancer*. 14:155, 2014.
- 251) Aoyama T, Yoshikawa T, Fujikawa H, Hayashi T, Ogata T, Cho H, Yamada T, Hasegawa S, Tsuchida K, Yukawa N, Oshima T, Oba MS, Morita S, Rino Y, Masuda M. Prognostic factors in stage IB gastric cancer. *World J Gastroenterol*. 20: 6580-6585, 2014.
- 252) Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, Arai T, Ito T, Komoike Y, Doi T, Masuda N, Miyauchi K, Miyoshi Y, Sakamoto J, Morita S, Taguchi T. Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. *Anticancer Res*. 34: 3583-3588, 2014.
- 253) Morita S. Yamamoto H, Sugitani Y. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation. *Stat Med* 33: 4008-4018, 2014.
- 254) Murakami K, Kohno M, Kadoya M, Nagahara H, Fujii W, Seno T, Yamamoto A, Oda R, Fujiwara H, Kubo T, Morita S, Nakada H, Hla T, Kawahito Y. Knock out of S1P3 receptor signaling attenuates inflammation and fibrosis in bleomycin-induced lung injury mice model. *PLOS ONE* 9: e106792,2014.
- 255) Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahashi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S for the COLM Investigators. Combinations of olmesartan and calcium channel blocker or diuretic in elderly hypertensive patients: a randomized, controlled trial. *J Hypertension* 32: 2054-2063, 2014.

- 256) Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M. A phase II study of metronomic paclitaxel / cyclophosphamide / capecitabine followed by 5-fluorouracil / epirubicin / cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. *Cancer Chem Pharm.* 74: 229-238,2014.
- 257) Mihara T, Uchimoto K, Morita S, Goto T. Effect of lidocaine in preventing laryngospasm in children: a systematic review and meta-analysis. *Anaesthesia.* 69:1388-1396,2014.
- 258) Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse ME, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial (Adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer: The SAMIT randomized controlled trial). *Lancet Oncol* 15:886-893.2014.
- 259) Kakizoe M, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Kishida T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Taguri M, Morita S, Inoue T, Kubota Y, Nakaigawa N. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. *BMC Cancer* 14:390,2014
- 260) Oba MS, Imoto S, Toh U, Wada N, Kawada M, Kitada M, Masuda N, Taguchi T, Minami S, Jinno H, Sakamoto J, Morita S. Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes. *Jpn J Clin Oncol.* 44: 876-879,2014.
- 261) Miyoshi Y, Uemura H, Umemoto S, Sakamaki K, Morita S, Suzuki K, Shibata Y, Masumori N, Ichikawa T, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Harada M, Kubota Y. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients. *BMC Cancer* 14: 717,2014.
- 262) Hamamoto Y, Yamaguchi T, Nishina T, Yamazaki K, Ura T, Nakajima T, Goto A, Shimada K, Nakayama N, Sakamoto J, Morita S, Yamada Y for the BIX study Group. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX Study). *The Oncologist.* 19: 1131-1132,2014.
- 263) Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, Sonobe M, Morita S, Date H, Hiraoka M. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy: Propensity score match analysis. *Eur J Cancer.* 50: 2932-2938,2014.
- 264) Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R, Sakamoto J, Oba

- MS, Morita S, Kono T, Tsuburaya A. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. *Cancer Chemother Pharmacol.* 73: 1047-54, 2014.
- 265) Watanabe J, Tatsumi K, Ota M, Suwa Y, Suzuki S, Watanabe A, Ishibe A, Watanabe K, Akiyama H, Ichikawa Y, Morita S, Endo I. The impact of visceral obesity on surgical outcomes of laparoscopic surgery for colon cancer. *Int J Colorectal Dis.*29: 343-351,2014.
- 266) Nakamura M, Nanto S, Hirayama A, Takayama T, Nishikawa M, Kimura K, Morita S, Aizawa T, Asano R, Matsumaru Y, Hamada C, Isshiki T. Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale. *Catheter Cardiovasc Interv.* 84: 368-374,2014.
- 267) Oshikawa J, Toya Y, Morita S, Taguri M, Hanaoka K, Hasegawa T, Kaizu K, Kamata K, Kobayashi S, Ohtake T, Sato T, Yasuda G, Kimura K, Umemura S. Angiotensin receptor blocker (ARB)–diuretic versus ARB–calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy. *Clin Exp Hypertens.* 36: 244-250,2014.
- 268) Ishikawa T, Sasaki T, Tanabe M, Narui K, Kida K, Shimada K, Shimizu D, Yamada A, Morita S, Oba MS, Kawachi K, Nozawa A, Ichikawa Y, Takabe K, Endo I. The Pathological Response to Anthracycline is Associated with Topoisomerase II α Gene Amplification in the HER2 Breast Cancer Subset. *J Surg Sci.* 2:10-12,2014.
- 269) Fukuda H, Numata K, Moriya S, Shimoyama Y, Ishii T, Nozaki A, Kondo M, Morimoto M, Maeda S, Sakamaki K, Morita S, Tanaka K. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. *Radiology.* 272:598-604,2014
- 270) Sasaki T, Kunisaki R, Kinoshita H, Kimura H, Kodera T, Nozawa A, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Morita S, Fujii S, Numata K, Tanaka K, Tanaka M, Maeda S. Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn's disease. *BMC Research Notes.*7:363,2014.
- 271) Fujii S, Ishibe A, Ota M, Yamagishi S, Watanabe K, Watanabe J, Kanazawa A, Ichikawa Y, Oba M, Morita S, Hashiguchi Y, Kunisaki C, Endo I. Short-term results of a randomized study between laparoscopic and open surgery in elderly colorectal cancer patients (Eld Lap study). *Surgical Endoscopy.*28:466-476,2014.
- 272) Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K, Hirashima T, Kogure Y, Kimura T, Takahashi T, Atagi S, Seto T, Sawa T, Yamamoto M, Satouchi M, Okuno M, Nagase S, Takayama K, Tomii K, Maeda T, Oizumi S, Fujii S, Akashi Y, Nishino K, Ebi N, Nakagawa K, Nakanishi Y, Nishio K. Multiplex genomic profiling of non-small cell lung

- cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. *Oncotarget*. 5:2293-2304,2014.
- 273) Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A, Tsuji A, Kaihara S, Ikoma H, Takemura S, Toyokawa H, Terajima H, Morita S, Ioka T. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). *Cancer Chemother Pharmacol*. 73:1295-1301,2014.
- 274) Miyagi E, Motoki Y, Asai-Sato M, Taguri M, Morita S, Hirahara F, Wark JD, Garland SM. Web-based Recruiting for a Survey on Knowledge and Awareness of Cervical Cancer Prevention among Young Women Living in Kanagawa Prefecture, Japan. *Int J Gynecol Cancer*. 24:1347-1355,2014.
- 275) Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, Ueki T, Udagawa K, Kitami K, Moriyama M, Miyoshi Y, Tsuchiya F, Ikeda I, Kobayashi K, Sato M, Morita S, Noguchi K, Uemura H. Androgen deprivation therapy prevents bladder cancer recurrence. *Oncotarget*. 5:12665-12674,2014.
- 276) Iwasawa T, Ogura T, Sakai F, Kanauchi T, Komagata T, Baba T, Gotoh T, Morita S, Yazawa T, Inoue T. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. *Eur J Radiol*. 83: 32-38, 2014.
- 277) Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients from JBCRG-Cohort Study 01. *Int J Clin Oncol*. 20: 709-722, 2015.
- 278) Shimada M, Morine Y, Nagano H, Hatano E, Kaiho T, Miyazaki M, Kono T, Kamiyama T, Morita S, Sakamoto J, Kusano M, Saji S, Kanematsu T, Kitajima M, for the JFMC40-1001 group. Effect of TU-100, a traditional Japanese medicine, after Hepatic Resection in Patients with Liver Cancer: a multi-center, randomized, double-blind, placebo-controlled phase II trial (JFMC40-1001). *Int J Clin Oncol*. 45: 650-656,2015.
- 279) Yasui H, Muro K, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Esaki T, Tokunaga S, Kuwano H, Boku N, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K. A phase 3 non-inferiority study of 5-FU / l-leucovorin / irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. *J Cancer Res Clin Oncol*. 141: 153-160,2015.
- 280) Takeda K, Morita S. Incorporating historical data in Bayesian phase I trial design: The Caucasian-to-Asian toxicity tolerability problem. *Therapeutic Innovation & Regulatory*

Science 49: 93-99, 2015

- 281) Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SI, Munakata M, Saitoh S, Nishio K, Morita S, Kim YH, Sakata Y. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. *Jpn J Clin Oncol.* 18: 824-832, 2015.
- 282) Aoyama T, Fujikawa H, Cho H, Ogata T, Shirai J, Hayashi T, Rino Y, Masuda M, Oba M, Morita S, Yoshikawa T. A methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective, randomized, controlled study. *Am J Surg Path.* 39: 266-273, 2015.
- 283) Hifumi T, Jinbo I, Okada I, Kiri N, Kato H, Koido Y, Inoue J, Abe Y, Kawakita K, Morita S, Kuroda Y. The impact of age on the outcomes of mechanical ventilation for community-acquired pneumonia in elderly patients admitted to the emergency department. *American Journal of Emergency Medicine.* 33: 277-281, 2015.
- 284) Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, Shiomi H, Kubo S, Ikuta S, Yanagimoto H, Terajima H, Ikoma H, Sakai D, Kodama Y, Seo S, Morita S, Ajiki T, Nagano H, Ioka T. A multi-institution phase II study of gemcitabine/cisplatin/S-1 combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). *Cancer Chemotherapy and Pharmacology.* 75: 293-300, 2015.
- 285) Hamaji M, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N, Sonobe M, Nagata Y, Hiraoka M, Date H. Long-term outcomes of video-assisted thoracoscopic surgery lobectomy versus stereotactic body radiotherapy for biopsy-proven clinical stage I non-small cell lung cancer: propensity-matched analysis. *The Annals of Thoracic Surgery.* 99: 1122-1129, 2015.
- 286) Tateya I, Morita S, Muto M, Miyamoto S, Hayashi T, Funakoshi M, Aoyama I, Hirano S, Kitamura M, Ishikawa S, Kishimoto Y, Morita M, Mahattanasakul P, Morita S, Ito J. Magnifying endoscope with NBI to predict the depth of invasion in laryngo-pharyngeal cancer. *Laryngoscope.* 125: 1124-1129, 2015.
- 287) Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S. A Phase II Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer Harboring Mutations of Epidermal Growth Factor Receptor (EGFR) after Failing First-Line EGFR-Tyrosine Kinase Inhibitors (HANSHIN Oncology Group 0109). *Lung Cancer.* 87: 136-140, 2015.
- 288) Hamatani Y, Ogawa H, Uozumi R, Iguchi M, Yamashita Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Morita S, Akao M. Low body weight is associated with the incidence of stroke in atrial fibrillation patients: Insight from the Fushimi AF Registry.

Circulation Journal. 79: 1009-1017,2015.

- 289) Koizumi W, Morita S, Sakata Y. A Randomized Phase III Trial of Weekly or 3-weekly Doses of nab-Paclitaxel versus Weekly Doses of Cremophor-Based Paclitaxel in Patients with Previously Treated Unresectable or Recurrent Gastric Cancer (ABSOLUTE trial). *Jap J Clin Oncol.* 45: 303-306,2015.
- 290) Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T on behalf of North East Japan Study Group and Tokyo Cooperative Oncology Group. Concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations (NEJ005/TCOG0902): a randomised phase 2 trial. *Annals of Oncology.* 26: 888-894,2015.
- 291) Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-First study of Kanto CML Study Group. *Am J Hematol.* 90: 282-287, 2015.
- 292) Fujii T, Nakao A, Murotani K, Okamura Y, Ishigure K, Hatsuno T, Sakai M, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Kodera Y. Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial. *Annals Surg Oncol* 22: 3905-3912,2015.
- 293) Hashimoto N, Tsuboi A, Kagawa N, Chiba Y, Izumoto S, Kinoshita M, Kijima N, Oka Y, Morimoto S, Nakajima H, Morita S, Sakamoto J, Nishida S, Hosen N, Oji Y, Arita N, Yoshimine T, Sugiyama H. Wilms tumor 1-peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: Safety and impact on immunological response. *Cancer Immunology.* 64: 707-716,2015.
- 294) Fujikawa H, Sakamaki K, Kawabe T, Hayashi T, Aoyama T, Sato T, Oshima T, Rino Y, Morita S, Masuda M, Ogata T, Cho H, Yoshikawa T. A new statistical model identified two-thirds of clinical T1 gastric cancers to be possible candidates for endoscopic treatment. *Annals Surg Oncol.* 22: 2317-2322, 2015.
- 295) Katsuno H, Maeda K, Kaiho T, Kunieda K, Funahashi K, Sakamoto J, Kono T, Hasegawa H, Furukawa Y, Imazu Y, Morita S, Watanabe M, Saji S, Kanematsu T, Kitajima M. Clinical efficacy of Daikenchuto (DKT) for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multi-center, placebo-controlled study (JFMC39-0902). *Jp J Clin Oncol.* 45: 650-655,2015.

- 296) Kaido T, Morita S, Tanaka S, Ogawa K, Mori A, Hatano E, Uemoto S. Long-term outcomes of hepatic resection versus liver transplantation for hepatocellular carcinoma: a propensity score-matching study. *Disease Markers* 425926,2015.
- 297) Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. *Br J Cancer*. 112: 1709-1716,2015.
- 298) Sakane N, Kotani K, Takahashi K, Sano Y, Tsuzaki K, Okazaki K, Sato J, Suzuki S, Morita S, Oshima Y, Izumi K, Kato M, Ishizuka N, Noda M, Kuzuya H. Effects of telephone-delivered lifestyle support on the development of diabetes in subjects at high risk of type 2 diabetes: J-DOIT1, a pragmatic cluster randomized trial. *BMJ Open* 5:e007316,2015
- 299) Morita S, Sakamaki K, Yin G. Detecting overall survival benefit derived from survival post-progression rather than progression-free survival. *J Natl Cancer Inst*. 107: djv133, 2015.
- 300) Hata A, Katakami N, Fujita S, Nanjo S, Takeshita J, Tanaka K, Kaneda T, Nishiyama A, Nishimura T, Nakagawa A, Otsuka K, Morita S, Urata Y, Negoro S. A Phase II Study of Pemetrexed Monotherapy in Chemo-naïve Eastern Cooperative Oncology Group Performance Status 2 Patients with EGFR Wild-type or Unknown Advanced Non-squamous Non-small Cell Lung Cancer (HANSHIN Oncology Group 002). *Cancer Chemotherapy and Pharmacology* 75: 1267-1272,2015.
- 301) Hatayama T, Morita S, Sakamaki K. Bayesian response adaptive randomization using longitudinal outcomes. *Pharmaceutical Statistics* 14: 369-376,2015.
- 302) Nishino K, Imamura F, Kumagai T, Katakami N, Hata A, Okuda C, Urata Y, Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M, Morita S, Negoro S. A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy (HANSHIN Oncology group 0110). *Lung Cancer*. 89: 146-153,2015.
- 303) Otsuka T, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S. Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results from a multicenter retrospective study (HANSIN Oncology Group 0212). *Anticancer Research* 35: 3885-3892, 2015.
- 304) Yamada K, Aono H, Hosomi Y, Okamoto H, Kato T, Komase Y, Nishikawa M, Azuma K, Takeoka H, Okuma Y, Nakahara Y, Sato A, Oba MS, Morita S, Kunitoh H, Watanabe K. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research

- Group 0911. *Eur J Cancer*. 51: 1904-1910,2015.
- 305) Miyoshi Y, Noguchi K, Yanagisawa M, Taguri M, Morita S, Ikeda I, Fujinami K, Miura T, Kobayashi K, Uemura H. Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer. *BMC Cancer*. 15:338,2015.
- 306) Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K, Suzuki M, Morita S, Taguri M, Tanaka K. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. *Hepatol Res*. 45:279-287,2015.
- 307) Matsuda C, Munemoto Y, Mishima H, Nagata N, Oshiro M, Kataoka M, Sakamoto J, Aoyama T, Morita S, Kono T. Double-Blind, Placebo-Controlled, Randomized Phase II Study of TJ-14 (Hangeshashinto) for Infusional Fluorinated-Pyrimidine-based Colorectal Cancer Chemotherapy-induced Oral Mucositis. *Cancer Chemother Pharmacol*. 76:97-103,2015.
- 308) Akiyama E, Sugiyama S, Matsubara J, Kurokawa H, Konishi M, Nozaki T, Ohba K, Fujisue K, Maeda H, Sakamoto K, Sugamura K, Sumida H, Jinnouchi H, Sakamaki K, Morita S, Kimura K, Umemura S, Ogawa H. Decreased Plasma Levels of Active Glucagon-Like Peptide-1 in Coronary Artery Disease. *J Am Coll Cardiol*. 65:754-755,2015.
- 309) Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Randomized phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy. *Eur J Cancer*. 51: 808-816,2015.
- 310) Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Factors Associated with Poor Response to Gefitinib in the NEJ002 Study: Smoking and L858R Mutation. *Lung Cancer*. 88:181-186,2015.
- 311) Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. *Am J Hematol*. 90: 819-824, 2015.
- 312) Nakamura M, Yamada Y, Muro K, Takahashi K, Baba H, Sasaki Y, Komatsu Y, Satoh T, Mishima H, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. The SOFT trial: a phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. *Future Oncol*. 11: 1471-1478, 2015.
- 313) Fujii T, Yamada S, Murotani K, Okamura Y, Ishigure K, Kanda M, Takeda S, Morita S,

Nakao A, Kodera Y. Oral food intake versus fasting on postoperative pancreatic fistula after distal pancreatectomy: A multi-institutional randomized controlled trial. *Medicine* 94: e2398, 2015.

- 314) Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S, on behalf of the DADI Trial Group, JAPAN. Discontinuation of second-line dasatinib in chronic myeloid leukaemia patients who have maintained deep molecular response for more than 1 year: the prospective, multicentre Dasatinib Discontinuation (DADI) Trial. *Lancet Haematology* 2: e528-535,2015
- 315) Yoshikawa K, Shimada M, Wakabayashi G, Ishida K, Kaiho T, Kitagawa Y, Sakamoto J, Shiraishi N, Koeda K, Mochiki E, Saikawa Y, Yamaguchi K, Watanabe M, Morita S, Kitano S, Saji S, Kanematsu T, Kitajima M. Effect of Daikenchuto, a Traditional Japanese Herbal Medicine, after Total Gastrectomy for Gastric Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. *J Am Coll Surg.* 221:571-578, 2015.
- 316) Sadahiro S, Morita S, Sasaki K, Sakamoto K, Ohge H, Takahashi T, Tsuchiya T, Sato T, Kondo K, Ogata Y, Masuko H, Baba H, Maeda K, Hamada M, Itabashi M, Nishimura G, Takahashi K, Ikeda M, Taguri M, Kodaira S. Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201). *Clin Colorectal Cancer.* 14:277-280, 2015.
- 2016**
- 317) Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, Kurita A, Uza N, Kodama Y, Asada M, Kawaguchi M, Masui T, Mizumoto M, Yazumi S, Matsumoto S, Takaori K, Morita S, Muto M, Uemoto S, Chiba T. Prognostic Model for Survival Based on Readily Available Pretreatment Factors in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy. *Int J Clin Oncol* 21: 118-125,2016.
- 318) Katsuno H, Maeda K, Ohya M, Yoshioka K, Tsunoda A, Koda K, Matsuoka H, Ohge H, Morita S, Saji S, Kanematsu T, Kitajima M. Clinical pharmacology of daikenchuto assessed by transit analysis using radiopaque markers in patients with colon cancer undergoing open surgery: A randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902 Additional Study). *Journal of Gastroenterology* 51: 222-229,2016.
- 319) Ishiguro T, Takayanagi N, Kanauchi T, Uozumi R, Kawate E, Takaku Y, Kagiya N, Shimizu Y, Hoshi T, Morita S, Sugita Y. Clinical and radiographic comparison of influenza virus-associated pneumonia among three viral subtypes. *Internal Medicine* 55: 731-737,2016.
- 320) Sakai R, Taguri M, Oshima K, Mori T, Ago H, Adachi S, Morita S, Taniguchi S, Fukuda S, Ohashi K, Eto T, Morishima T, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Murata M. A

- Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft-Versus-Host Disease Prophylaxis, Stratified by Stem Cell Source: A Retrospective Nationwide Survey International Journal of Hematology. *Int J Hematol* 103: 322-333, 2016.
- 321) Okada K, Kawai M, Hirono S, Fujii T, Kodera Y, Sho M, Nakajima Y, Satoi S, Kwon AH, Shimizu Y, Ambo Y, Kondo N, Murakami Y, Ohuchida J, Eguchi H, Nagano H, Oba MS, Morita S, Sakamoto J, Yamaue H; JAPAN-PD Investigators. Evaluation of the efficacy of daikenchuto (TJ-100) for prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial. *Surgery* 159: 1333-1341, 2016
- 322) Nagakura J, Yamakawa T, Taguri M, Tsuchiya H, Shigematsu E, Suzuki J, Morita S, Kadonosono K, Terauchi Y. Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes. *Endocrine Journal* 63: 239-247, 2016.
- 323) Nishio H, Minakata K, Kawaguchi A, Kumagai M, Ikeda T, Shimizu A, Yokode M, Morita S, Sakata R. Transcutaneous oxygen pressure as a surrogate index of lower limb amputation. *International Angiology*; 35: 565-572, 2016.
- 324) Ito Y, Yoshikawa T, Fujiwara M, Kojima H, Matsui T, Mochizuki Y, Cho H, Aoyama T, Ito S, Misawa K, Nakayama H, Morioka Y, Ishiyama A, Tanaka C, Morita S, Sakamoto J, Kodera Y. Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: A randomized controlled trial. *Gastric Cancer*. 19: 977-985, 2016.
- 325) Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. Safety and Anti-tumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients with Platinum-resistant Ovarian Cancer. *J Clin Oncol*. 33: 4015-4022, 2015.
- 326) Nakanishi K, Kobayashi D, Mochizuki Y, Ishigure K, Ito S, Kojima H, Ishiyama A, Fujitake S, Shikano T, Morita S, Sakamoto J, Kodera Y. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701). *Int J Clin Oncol* 21: 557-565, 2016.
- 327) Ishiguro T, Takayanagi N, Uozumi R, Tada M, Kagiya N, Takaku Y, Shimizu Y, Sugita Y, Morita S. The Long-term Clinical Course of Chronic Eosinophilic Pneumonia. *Internal Medicine*. 55: 2373-2377, 2016.
- 328) Takano M, Yamamoto K, Tabata T, Minegishi Y, Yokoyama T, Hirata E, Ikeda T, Shimada M, Yamada K, Morita S, Ando Y, Hirata K, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum. *Asia Pacific Journal of Clinical Oncology*. 12: 115-124, 2016.

- 329) Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. *Jp J Clin Oncol.* 46: 462-467, 2016.
- 330) Kodera Y, Takahashi N, Yoshikawa T, Takiguchi N, Fujitani K, Ito S, Miyamoto K, Takayama O, Imano M, Kobayashi D, Miyashita Y, Morita S, Sakamoto J. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. *Gastric Cancer.* 20: 190-199, 2017.
- 331) Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami H, Nakagawa K, Negoro S, Nakanishi Y. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. *J Clin Oncol.* 34: 3248-3257, 2016.
- 332) Yokota T, Tachibana H, Konishi T, Yurikusa T, Hamauchi S, Sakai K, Nishikawa M, Suzuki M, Naganawa Y, Hagihara T, Tsumaki H, Kubo T, Sato M, Taguri M, Morita S, Eguchi T, Kubota K, Zenda S. Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy. *Supportive Care in Cancer.* 24: 3029-3036, 2016.
- 333) Kawaguchi K, Yamamoto M, Yamaguchi A, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. *Breast Cancer.* 24: 111-120, 2017.
- 334) Kuroda, Y., Asada, R., So, K., Yonezawa, A., Nankaku, M., Mukai, K., Ito-Ihara, T., Tada, H., Yamamoto, M., Murayama, T., Morita, S., Tabata, Y., Yokode, M., Shimizu, A., Matsuda, S., Akiyama, H. A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head. *International Orthopaedics.* 40: 1747-1754, 2016.
- 335) Yoshikawa T, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, Fujitani K, Kimura Y, Fujita J, Aoyama T, Hayashi T, Cho H, Tsuburaya A, Miyashita Y, Sakamoto J. Survival results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. *Eur J Cancer.* 62: 103-111, 2016.
- 336) Tsuburaya A, Sugimoto N, Kawabata R, Kazuhiro N, Imamoto H, Tsujinaka T, Esaki T, Horita Y, Kimura Y, Fujiya T, Takayama O, Oono R, Yabusaki H, Taguri M, Morita S, Yamada Y, Boku N, Koizumi W, Tan P, Ninomiya M, Furukawa H, Sasako M. Molecular

- biomarker study in randomized phase III trial of irinotecan plus S-1 vs S-1 for advanced gastric cancer, GC0301/TOP-002. *Clinical Oncology*. 28: e45-51, 2016.
- 337) Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, Chiba Y, Izumoto S, Eliseeva O, Ichinohasama R, Sakamoto J, Morita S, Nakajima H, Takashima S, Nakae Y, Nakata J, Kawakami M, Nishida S, Hosen N, Fujiki F, Morimoto S, Adachi M, Iwamoto M, Oka Y, Yoshimine T, Sugiyama H. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. *Int J Cancer*. 139: 1391-1401, 2016.
- 338) Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T1, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). *Gastric Cancer*. 19: 839-851, 2016.
- 339) Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). *Annals Oncol*. 27: 1539-1546, 2016.
- 340) Ohwada S, Morita S. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial. *Pharma Stat*. 15: 420-429, 2016.
- 341) Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh M, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Randomized phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). *Eur J Cancer*. 65: 164-171, 2016.
- 342) Sekiguchi M, Fujii T, Matsui K, Murakami K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H. Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naïve rheumatoid arthritis: results from the ABROAD study. *J Rheumatol*. 43: 1974-1983, 2016.
- 343) Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, Morita S, Carbone DP. Relationship between overall survival and response or progression-free survival in

advanced non-small cell lung cancer patients treated with anti PD-1/PD-L1 antibodies. *Journal of Thoracic Oncology*. 11: 1927-1939, 2016.

- 344) Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). *Eur J Cancer*. 65: 164-171, 2016.

Ishiguro T, Kagiyama N, Uozumi R, Odashima K, Kurashima K, Morita S, Takayanagi N. Risk factors for the severity and mortality of pneumococcal pneumonia: Importance of premorbid patients' performance status. *Journal of Infection and Chemotherapy*. 22: 685-691, 2016.

2017

- 345) Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, Nishida Y, Iwasa S, Miwa H, Masuishi T, Boku N, Yamada Y, Koderu Y, Yoshida K, Morita S, Sakamoto J, Saji S, Kitagawa Y. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). *Int. J Cancer*. 140: 188-196, 2017.
- 346) Yoneshima Y, Morita S, Ando M, Miura S, Yoshioka H, Abe T, Kato T, Kondo M, Hosomi Y, Hotta K, Yamamoto N, Nakanishi Y, Okamoto I. Treatment Rationale and Study Design for the J-AXEL Study: A Randomized Phase III Study Comparing nab-Paclitaxel with Docetaxel in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*. 18: 100-103, 2017.
- 347) Morita S, Thall PF, Takeda K. A Simulation Study of Methods for Selecting Subgroup-Specific Doses in Phase I Trials. *Pharm Stat*. 16: 143-156, 2017.
- 348) Hori M, Yasumi T, Shimodera S, Shibata H, Hiejima E, Oda H, Izawa K, Kawai T, Ishimura M, Nakano N, Shirakawa R, Nishikomori R, Takada H, Morita S, Horiuchi H, Ohara O, Ishii E, Heike T. A CD57+ CTL degranulation assay effectively identifies familial hemophagocytic lymphohistiocytosis type 3 patients. *Journal of Clinical Immunology*. 37: 92-99, 2017.
- 349) Yano T, Kasai H, Horimatsu T, Yoshimura K, Teramukai S, Morita S, Tada H, Yamamoto Y, Kataoka H, Kakushima N, Ishihara R, Isomoto H, Muto M. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. *Oncotarget*. 8: 22135-22144, 2017.
- 350) Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyaama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Incidence of Hepatitis B Virus Reactivation in

Patients with Resolved Infection on Immunosuppressive Therapy for Rheumatic Disease: A Multi-centre Prospective Observational Study in Japan. *Annals of the Rheumatic Diseases*. 76: 1051-1056, 2017.

- 351) Kurata M, Sumiyoshi S, Sonobe M, Menju T, Momose M, Koyama M, Shigeto S, Fujimoto M, Zhang M, Morita S, Date H. Lung adenocarcinoma with MUC4 expression is associated with smoking status, HER2 protein expression, and poor prognosis: Clinicopathologic analysis of 338 cases. *Clinical Lung Cancer*. 18: e273-281, 2017.
- 352) Baba H, Yamada Y, Takahari D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Takinishi Y, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomized phase 3: SOFT study. *ESMO Open*. 2: e000135, 2017.
- 353) Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse M, Ryoo BY, Shen L, Sakamoto J, Kim TW. Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. *Chinese Journal of Cancer*. 35: 102, 2016.
- 354) Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomized, non-inferiority, phase III trial. *Lancet Gastroenterol Hepatol*. 2: 277-287, 2017.
- 355) Hata A, Katakami N, Hattori Y, Tanaka K, Fujita S, Kotani Y, Nishimura T, Imamura F, Yokota S, Satouchi M, Monden K, Otsuka K, Nishiyama A, Tsubouchi K, Kaneda T, Yoshioka H, Morita S, Negoro S. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥ 80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003) *Cancer Chemother Pharmacol*. 79: 689-695, 2017.
- 356) Nakabo S, Hashimoto, M, Ito S, Kataoka T, Furu M, Ito H, Fujii T, Yoshifuji H, Imura Y, Nakashima R, Murakami K, Kuramoto N, Tanaka M, Satoh J, Ishigami A, Haga H, Morita S, Mimori T, Ohmura K. Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. *Rheumatology*. 56: 1217-1226, 2017.
- 357) Morita S, Mueller P. Bayesian population finding with biomarkers in a randomized clinical

- trial. *Biometrics*. 73, 1355–1365, 2017.
- 358) Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun YH, Tsuji Hi, Wada H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M. Current status and outcomes of direct oral anticoagulant use in Real-World Atrial Fibrillation Patients - Fushimi AF Registry. *Circulation Journal*. 81: 1278-1285, 2017.
- 359) Yoneshima Y, Morita S, Ando M, Miura S, Yoshioka H, Abe T, Kato T, Kondo M, Hosomi Y, Hotta K, Yamamoto N, Kishimoto J, Nakanishi Y, Okamoto I. Treatment rationale and design for J-AXEL: A randomized phase 3 study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small-cell lung cancer. *Clinical Lung Cancer*. 18, 100-103, 2017.
- 360) Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M. Outcomes of fulvestrant therapy among Japanese women with advanced breast cancer: A retrospective multicenter cohort study (JBCRG-C06; Safari). *Breast Cancer Research and Treatment*. 163: 545-554, 2017.
- 361) Inoue H, Nagase T, Morita S, Yoshida A, Jinnai T, Ichinose M. Prevalence and characteristics of asthma–COPD overlap syndrome identified by a stepwise approach. *Int J Chron Obstruct Pulmon Dis*. 12:1803-1810, 2017.
- 362) Tanaka S, Ueno T, Ishiguro H, Morita S, Toi M. The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients. *Precision Oncology*. 1: 6, 2017.
- 363) Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease (a secondary publication). *Renal Replacement Therapy*. 3:36: DOI 10.1186/s41100-017-0114-y, 2017.
- 364) Nishi H, Ishii A, Nakahara I, Matsumoto S, Sadamasa N, Kai Y, Ishibashi R, Saka M, Ando M, Okata T, Miyata H, Sonoda K, Koge J, Yamamoto M, Morita S, Nagata I. Different learning curves between stent retrieval and a direct aspiration first-pass technique for acute ischemic stroke. *The Journal of Neurosurgery*. 129: 1456-1463, 2018.
- 365) Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. *Int J Clin Oncol*. 22: 972-979, 2017.
- 366) Hida K, Okamura R, Sakai Y, Konishi T, Akagi T, Yamaguchi T, Akiyoshi T, Fukuda M,

- Yamamoto S, Yamamoto M, Nishigori T, Kawada K, Hasegawa S, Morita S, Watanabe M. Open versus laparoscopic surgery for advanced low rectal cancer: a large, multicenter, propensity score matched cohort study in Japan. *Annals of Surgery*. 268: 318-324, 2018.
- 367) Nagami S, Oku Y, Yagi N, Sato S, Uozumi R, Morita S, Yamagata Y, Kayashita J, Tanimura K, Sato A, Takahashi R, Muro S. Breathing-swallowing discoordination is associated with frequent exacerbations of COPD. *BMJ Open Respiratory Research*. 4: e000202, 2017.
- 368) Tanioka M, Yamaguchi S, Shimada M, Nagao S, Takehara K, Nishimura M, Morita S, Negoro S, Fujiwara K, Kigawa J. Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: A prospective multicenter phase II trial with a dose-finding study. *Medical Oncology*. 34: 134, 2017.
- 369) Tanaka H, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Mochizuki Y, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003). *Int J Clin Oncol*. 22: 1052-1059, 2017.
- 370) Kono T, Shimada M, Nishi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Ohtake Y, Sato Y, Kanematsu T, Kitajima M. Daikenchuto administration for intestinal hypomotility after open abdominal surgery: a pooled analysis of three randomized controlled trials. *Annals of Cancer Research and Therapy*. 25: 41-43, 2017.
- 371) Nishikawa K, Koizumi W, Tsuburaya A, Yamanaka T, Morita S, Fujitani K, Akamaru Y, Shimada K, Hosaka H, Nakayama N, Tsujinaka T, Sakamoto J. Meta-analysis of patient-level data on biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer with the TCOG GI-0801 BIRIP and ECRIN TRICS RCTs: protocol paper. *Ann. Cancer Res. Ther*. 25: 48-51, 2017.
- 372) Nokihara H, Lu S, Mok T, Nakagawa K, Yamamoto N, Shi Y, Zhang L, Soo R, Yang JCH, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Heng Y, Lim WT, Morita S, Tamura T. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). *Ann Oncol*. 28: 2698-2706, 2017.
- 373) Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, Mizuma H, Takahashi R, Inoue H, Morita S, Yamamoto M, Okita K, Nakagawa M, Parmar M, Takahashi J. Human iPSC cell-derived dopaminergic neurons function in a primate Parkinson's disease model. *Nature*. 548: 592-596, 2017.
- 374) Kimura K, Ikoma A, Shibakawa M, Shimoda S, Imamura J, Osawa Y, Harada K, Saio M,

- Hishima T, Okusaka T, Morita S, Inoue K, Kanto T, Todaka K, Nakanishi Y, Mizokami M. Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP/ β -catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: a single-center, open-label, dose escalation, phase 1 trial. *EBioMedicine*. 23:79-87, 2017.
- 375) Rokutan-Kurata M, Yoshizawa A, Sumiyoshi S, Sonobe M, Menju T, Momose M, Koyama M, Shigeto S, Fujimoto M, Zhang M, Morita S, Date H, Haga H. Lung adenocarcinoma with MUC4 expression is associated with smoking status, HER2 protein expression, and poor prognosis: clinicopathologic analysis of 338 cases. *Clin Lung Cancer*. 18: e273-e281, 2017.
2018
- 376) Kukida Y, Kasahara A, Seno T, Inoue T, Sagawa R, Kida T, Nakabayashi A, Nagahara H, Murakami K, Sugitani T, Morita S, Ito H, Oda R, Fujiwara H, Kohno M, Kawahito Y. Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands. *Int J Rheum Dis*. 21: 1678-1685, 2018.
- 377) Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. *Lancet Gastroenterol Hepatol*. 3: 37-46, 2018.
- 378) Hattori M, Ishiguro H, Masuda N, Yoshimura A, Ohtani S, Yasojima H, Morita S, Ohno S, Iwata H. Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer - JBCRG -18 Cape Study. *Breast Cancer*. 25: 108-117, 2018.
- 379) Hibi K, Sonoda S, Kawasaki M, Otsuji Y, Murohara T, Ishii H, Sato K, Koshida R, Ozaki Y, Sata M, Morino Y, Miyamoto T, Amano T, Morita S, Kimura K, Fujiwara H. Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in coronary syndrome. *Circulation Journal*. 82: 757-766, 2018.
- 380) Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K. Dasatinib cessation after deep molecular response exceeding 2 years, and NK cell transition during dasatinib consolidation. *Cancer Science*. 109: 182-192, 2018.
- 381) Okuno K, Aoyama T, Oba K, Yokoyama N, Matsubayashi N, Kunieda K, Mnishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S. Randomized Phase III Trial Comparing surgery alone to UFT+PSK for Stage II Rectal Cancer (JFMC38 trial). *Cancer Chemother Pharmacol*. 81: 65-71, 2018.
- 382) Kusumoto T, Sakamoto Y, Baba H, Sugihara K, Okabe M, Yoshida K, Aiba K, Ota M, Yamauchi J, Mochizuki I, Maeda A, Morita S, Kunieda K, Itabashi M, Kotake K, Takahashi K, Sunami E, Ishiguro M, Tomita N, Boku N. Planned safety analysis of the ACTS-CC 02

- trial: A randomized phase III trial of S-1 plus oxaliplatin (SOX) versus tegafur–uracil plus leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer. *Clinical Colorectal Cancer*. 17: e153-161, 2018.
- 383) Sakamaki K, Kito Y, Yamazaki K, Izawa N, Tsuda T, Morita S, Boku N. Exploration of time points and cut-off values for early tumor shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size. *ESMO Open*. 2: e000275, 2017.
- 384) Takahashi F, Morita S. Optimal dose selection accounting for patient subpopulations in a randomized phase II trial to maximize the success probability of a subsequent phase III trial. *J Biopharm Stat*. 28, 870-883, 2018.
- 385) Takeda K, Morita S. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial. *Pharm Stat*. 7: 372-382, 2018.
- 386) Chow LW, Morita S, Chow CY, Ng WK, Toi M. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict value. *Endocr Relat Cancer*. 25: 123-130, 2018.
- 387) Asano F, Ishida T, Shinagawa N, Sukoh N, Anzai M, Kanazawa K, Tsuzuku A, Morita S. Virtual bronchoscopic navigation without X-ray fluoroscopy to diagnose peripheral pulmonary lesions: A randomized trial. *BMC Pulmonary Medicine*. 17: 184. 2017.
- 388) Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H. WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies. *Int J Cancer*. 142: 2375-2382, 2018.
- 389) Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T. Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. *ESMO Open*. 3: e000313, 2018.
- 390) Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial. *Annals Oncol*. 29: 624-631, 2018.

- 391) Noriyoshi Iriyama N, Kazuteru O, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. The efficacy of reduced-dose Dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: The LD-CML Study of the Kanto CML Study Group. *Intern Med.* 57: 17-23, 2018.
- 392) Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S. Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). *Int J Hematol.* 107: 578-585, 2018.
- 393) Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Nakajima T. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. *J Clin Oncol.* 36: 1000-1006, 2018.
- 394) Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K, Fukuoka M. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: long-term follow-up of a large patient cohort. *Lung Cancer.* 117: 14-19, 2018.
- 395) Takeda K, Taguri M, Morita S. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes. *Pharm Stat.* 17: 383-395, 2018.
- 396) Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. *Lancet Oncol.* 19: 660-671, 2018.
- 397) Sakamoto K, Honda G, Beppu T, Kotake K, Yamamoto M, Takahashi K, Endo I, Hasegawa K, Itabashi M, Hashiguchi Y, Kotera Y, Kobayashi S, Yamaguchi T, Morita S, Miyazaki M, Sugihara K. Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. *J Hepatobiliary Pancreat Sci.* 25:115–123, 2018.
- 398) Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. *Leukemia Research.* 66, 66-72, 2018.

- 399) Nishikawa K, Tsuburaya A, Takahashi M, Tanabe K, Yamaguchi K, Yoshino S, Namikawa T, Yoshikawa T, Rino Y, Kawada J, Tsuji A, Taira K, Kawabata R, Kodera Y, Hirashima Y, Yabusaki H, Hirabayashi N, Fujitani K, Miyashita Y, Morita S, Sakamoto J. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with an early relapse after S-1 adjuvant therapy, XP after TS-1 adjuvant failure (XParTS-I trial). *Gastric Cancer*. 21: 811-818, 2018.
- 400) Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Saito Oba M, Sato M, Morimoto S, Fujiki F, Eguchi H, Nagano H, Kumanogoh A, Unno M, Kon M, Shimada H, Ito K, Homma S, Oka Y, Morita S, Sugiyama H. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: A phase II randomized study. *Cancer Immunology Research*. 6: 320-331, 2018.
- 401) Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K. Prognostic factors and efficacy of first-Line chemotherapy in patients with advanced thymic carcinoma: a retrospective analysis of 286 patients from NEJ023 Study. *Oncologist*. 23: 1210-1217, 2018.
- 402) Fujimoto H, Yamaguchi O, Hayami H, Shimosaka M, Tsuboi S, Sato M, Morita S, Saito M, Kurahashi K, Goto T Efficacy of continuous versus intermittent subglottic secretion drainage in preventing ventilator-associated pneumonia in patients requiring mechanical ventilation: A single-center randomized controlled trial. *Oncotarget*. 9: 15876-15882, 2018.
- 403) Kaido T, Shinoda M, Inomata Y, Yagi T, Akamatsu N, Takada Y, Ohdan H, Shimamura T, Ogura Y, Eguchi S, Eguchi H, Ogata S, Yoshizumi T, Ikegami T, Yamamoto M, Morita S, Uemoto S. Effect of herbal medicine Daikenchuto on oral and enteral caloric intake after liver transplantation: a multicenter, randomized controlled trial. *Nutrition*. 54: 68-75, 2018.
- 404) Iizumi S, Takashima A, Sakamaki K, Morita S, Boku N. Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. *Cancer Chemother Pharmacol*. 81: 981-989, 2018.
- 405) Kimura S, Usuki K, Kukita T, Yoshihara S, Sakamoto J, Fukutani H, Ando S, Nohgawa M, Onishi Y, Sato T, Shikami M, Sakoda H, Ohe Y, Hashino S, Fukushima T, Yamazaki H, Adachi Y, Morita S, Nomura T, Shibayama H, Tsubaki K, Nataduka T, Mizuta S, Yokoyama H, Okamoto T, Shirasugi Y, Kosugi H, Uike N, Uoshima N, Nakagawa Y, Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Takeoka T, Akasaka H, Utsumi T, Wakita H, Minami Y, Ogasawara M. Final 3-year results of the Dasatinib Discontinuation Trial in Patients with Chronic Myeloid Leukemia who received dasatinib as a second-line treatment. *Clin Lymphoma Myeloma Leuk*.

18: 353-360, 2018.

- 406) Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): Therapeutic efficacy and clinical implications of circulating endothelial cells. *Cancer Medicine*. 7: 2442-2451, 2018.
- 407) Nishikawa K, Aoyama T, Oba MS, Yoshikawa T, Matsuda C, Munemoto Y, Takiguchi N, Tanabe K, Nagata N, Imano M, Oshiro M, Fukushima R, Kataoka M, Morita S, Tsuburaya A, Mishima H, Kono T, Sakamoto J. The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). *Journal of Cancer*. 9: 1725-1730, 2018.
- 408) Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase II study. *Cancer Medicine*. 7: 3044-3056, 2018.
- 409) Matsuo T, Hashimoto M, Itoh I, Kubo T, Uozumi R, FuruM, HItO, T Fujii, Tanaka M, Terao C, Kono H, Mori M, Hamaguchi M, Yamamoto W, Ohmura K, Morita S, Mimori T. Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study. *Scand J Rheumatol*. 48: 87-94, 2019.
- 410) Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: An exploratory analysis of the phase III ABSOLUTE trial. *Gastric Cancer*. 22: 155-163, 2019.
- 411) Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Tetsuo H, Ikai I, Morita S, Ioka T. A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancers (KHBO 1208): Kansai Hepato-Biliary Oncology Group. *Annals of Surgery*. 270: 230-237, 2019.
- 412) Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T; Kansai Hepato-Biliary Oncology (KHBO) Group. A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO

- 1208): Kansai Hepato-Biliary Oncology Group. *Ann Surg.* 270: 230–237, 2019.
- 413) Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H, and the ABROAD study investigators. Predictive factors for structural remission using abatacept: results from the ABROAD study. *Modern Rheumatology.* 29: 406-412, 2019.
- 414) Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, Takahashi T, Sakemura R, Kojima H, Kohno A, Oba M, Morita S, Sakamoto J, Emi N. Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. *Int J Clin Oncol.* 23: 980-988, 2018.
- 415) Azuma K, MNishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K. ASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer. *Cancer Science.* 109: 2532-2538, 2018.
- 416) Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial. *Cancer Medicine.* 7: 4217-4227, 2018.
- 417) Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S on behalf of HANSHIN Oncology Group. Afatinib plus Bevacizumab Combination After Acquired Resistance to EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase II Trial (ABC-Study). *Cancer.* 124: 3830-3838, 2018.
- 418) Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. *Breast Cancer (Auckl).* 12: 1178223418786243, 2018.
- 419) Yoshino T, Oki E, Nozawa H, Eguchi T, Nakajima, Taniguchi H, Morita S, Takenaka N, Ozawa D, Shiraoh K. Rationale and Design of the TRUSTY Study: A Randomized Multicenter Open-Label Phase II/III Study of Trifluridine/Tipiracil plus Bevacizumab versus

- Irinotecan, Fluoropyrimidine plus Bevacizumab as Second-line Treatment in Patients with Metastatic Colorectal Cancer Progressive During or Following First-Line Oxaliplatin-based Chemotherapy. *ESMO Open*. 3: e000411, 2018.
- 420) Yoshida T, Hashimoto M, Kawahara R, Yamamoto H, Tanaka M, Ito H, Masuda I, Hosoda K, Yamamoto W, Uozumi R, Morita S, Fujii Y, Mimori T, Nin K. Non-obese Visceral Adiposity Is Associated With the Risk of Atherosclerosis in Japanese Patients With Rheumatoid Arthritis: A Cross-Sectional Study. *Rheumatology international*. 38: 1679-1689, 2018.
- 421) Takeda K, Komatsu K, Morita S. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology. *Pharm Stat*.17: 725-733, 2018.
- 422) Nishikawa K, Tsuburaya A, Yoshikawa T, Kobayashi M, Kawada J, Fukushima R, Kojima H, Tanabe K, Yamaguchi K, Yoshino S, Takahashi M, Hirabayashi N, Sato S, Nemoto H, Rino Y, Nakajima J, Aoyama T, Miyagi Y, Oriuchi N, Miyashita Y, Morita S, Sakamoto J. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). *Eur J Cancer*.101: 220-228, 2018.
- 423) Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Chun-Ming Tsai, James Chih-Hsin Yang, Nishio M, Sang-We Kim, Kiura K, Inoue A, Takeda K, Jin-Hyoung Kang, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Clinical activity of ASP8273 in Asian patients with non - small - cell lung cancer with EGFR activating and T790M mutations. *Cancer Science*. 109: 2852-2862, 2018.
- 424) Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Lida H, Morita S, Bahceci E, Kaneko M, Kusano M, Yamada S, Takeshita S, Miyawaki S, Naoe T. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open - label phase 1 study. *Cancer Science*. 109: 3235–3244, 2018.
- 425) Uchibori K, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Aoe K, Mori M, Morita S, Negoro S. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. *Lung Cancer*. 124:65-70, 2018.
- 426) Yamamoto Y, Ueno T, Kashiwaba M, Taira N, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, and Iwata H. A randomized, open-label, phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. *Japanese Journal of Clinical Oncology*. 48: 855-859, 2018

- 427) Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Tamura D, Morita S, Negoro S. Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients? *Oncotarget*. 9: 34765-34771, 2018.
- 428) Petit C, Samson A, Morita S, Ursino M, Guedj J, Jullien V, Comets E, Zohar S. Unified approach for extrapolation and bridging of adult information in early phase dose-finding paediatric studies. *Stat Methods Med Res*. 27: 1860-1877, 2018.
- 429) Masuda N, Toi T, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. *Breast Cancer*. 25: 407-415, 2018.
- 2019
- 430) Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Morita S, Toi M. Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. *Breast Cancer*. 26:282-289, 2019.
- 431) Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Akio Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Takahashi T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S. Feasibility of the Imatinib Stop Study in the Japanese Clinical Setting: Delightedly Overcome CML Expert Stop TKI Trial (DOMEST Trial). *Int J Clin Oncol*. 24(4):445-453, 2019.
- 432) Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K, Hatakeyama S, Sakurai T, Kawamura S, Ishidoya S, Hoshi S, Ishida M, Mizuno K, Ogura K, Goto T, Terada N, Kobayashi T, Yamasaki T, Inoue T, Tsuchiya N, Ohyama C, Arai Y, Habuchi T, Morita S, Ogawa O. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. *Euro Urol Oncol*. 2(3):338-339, 2019.
- 433) Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T. Japanese Subgroup Analysis of a Phase III Study of S-1 versus Docetaxel in Non-Small Cell Lung Cancer Patients After Platinum-Based Treatment: EAST-LC. *Int J Clin Oncol*. 24(5):485-493, 2019.
- 434) Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunozuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F,

- Tsubata Y, Fujita Y, Morikawa N, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K. Erlotinib plus bevacizumab versus erlotinib alone in advanced lung cancer with EGFR mutations (NEJ026): interim analysis of an open-label, randomized, multicenter, phase 3 study. *Lancet Oncol.* 20(5):625-635, 2019.
- 435) Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. *Lung Cancer.* 128:113-119, 2019.
- 436) Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S; Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. *Transpl Int.* 32: 356-368, 2019.
- 437) Iwamura S, Kaido T, Morita S, Miyachi Y, Yao S, Shirai H, Kobayashi A, Hamaguchi Y, Kamo N, Yagi S, Uemoto S. Risk-benefit point of the model for end-stage liver disease score in patients waiting for deceased-donor liver transplantation: a single-center experience. *Hepatol Res.* 49: 687-694, 2019.
- 438) Maeda H, Iwamoto S, Morita Y, Takemoto H, Morita S, Munemoto Y, Mishima H, Naoki Nagata N, Toyofuku A, Tanaka C, Sakamoto J, Hirata K, Nagasaka T, Yoshihiro Hotta Y, Yoshida Y, Ishibashi K, Imasato M, Makiyama A. Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study). *Medical Oncology.* 36(6) Article number:46, 2019. DOI:10.1007/s12032-019-1254-4
- 439) Kono T, Shimada M, Nishi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Sato Y, Maehara Y, Kanematsu T, Kitajima M. Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials. *Surgery Today* 49(8):704-711, 2019.
- 440) Nishikawa K, Murotani K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Hasegawa H, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. A study of second-line irinotecan plus cisplatin versus irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: -Exploratory subgroup analysis of the randomized phase III TRICS trial. *Cancer Chemotherapy and Pharmacology.* 83: 867-874, 2019.
- 441) Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N,

- Nakagawa K. Phase I/II study of osimertinib with bevacizumab in EGFR-mutated, T790M-positive patients with progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). *Clin Lung Cancer*. 20: e492-e494, 2019.
- 442) Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K. Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study) *Lung Cancer*, 131: 128-133, 2019.
- 443) Yagi S, Kamo N, Morita S, Yamamoto G, Okajima H, Hamaguchi Y, Uemoto S, Kaido T, Taura K, Masano Y, Nagai K, Ogawa E, Hata K, Iwaki K. Impact of graft quality and fluid overload on postoperative massive ascites after living-donor liver transplantation. *Transplant Proc*. 51: 1779-1784, 2019.
- 444) Narui K, Shimizu D, Yamada A, Tanabe M, Sasaki T, Mari S. Oba, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Niikura N, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. *The Breast*. 47: 1-9, 2019.
- 445) Misawa K, Mochizuki Y, Sakai M, Teramoto H, Morimoto D, Nakayama H, Tanaka N, Matsui T, Ito Y, Ito S, Tanaka K, Uemura K, Morita S, Kodera Y. on behalf of the Chubu Clinical Oncology Group (CCOG) Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial). *British Journal of Surgery*. 107: 120-120, 2019.
- 446) Soh J, Toyooka S, Okumura N, Nakamura H, Nakata M, Yamashita M, Sakamoto J, Aoe M, Hotta K, Morita S, Date H. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. *Int J Clin Oncol*. 24: 1367-1376, 2019.
- 447) Nishikawa K, Koizumi W, Tsuburaya A, Yamanaka T, Morita S, Fujitani K, Akamaru Y, Shimada K, Hosaka H, Nakayama N, Tsujinaka T, Sakamoto J. Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. *Gastric Cancer*, 23: 160-167, 2019.
- 448) Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Azuma I, Kumanogoh A, Kawase I, Oka Y, Morita S, Sugiyama H. Immune adjuvant therapy using bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments. *Medicine*. 98: e16771, 2019.

- 449) Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor–positive breast cancer: a multicenter, open-label, phase II study. *Cancer Medicine*. 8(12):5468-5481, 2019.
- 450) Ota Tsutsumi I, Kunisawa S, Yoshida C, Seki M, Komeno T, Fushimi K, Morita S, Imanaka Y. Impact of Oral Voriconazole during Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Japanese Nationwide Retrospective Cohort Study. *Int J Clin Oncol*. 24(11):1449-1458, 2019.
- 451) Iwaki K, Yagi S, Morita S, Hamaguchi Y, Masano Y, Yamamoto G, Ogawa E, Nagai K, Kamo N, Hata K, Taura K, Okajima H, Kaido T, Uemoto S. Impact of graft quality and fluid overload on postoperative massive ascites after living donor liver transplantation. *Transplantation Proceedings*, 51: 1779e1784, 2019.
- 452) Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K, Mitsudomi T. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer. *Annals of Oncol*, 30: 1978–1984, 2019
- 453) Imamura K, Izumi Y, Uozumi R, Morita S, Banno H, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Takahashi N, Ikeda T, Ito T, Kusunoki Y, Shimizu A, Morinaga A, Koide Y, Hirohashi T, Fujii Y, Takahashi R, Inoue H. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: Protocol for a phase 1 dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. *BMJ Open*. 9(12) 2019. DOI 10.1136/bmjopen-2019-033131
- 454) Ahn J, Morita S, Wang W, Yuan Y. Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. *Stat Methods Med Res*. 28: 70-83, 2019.
- 455) Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arie K, Kitaori T, Hagiwara H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. *Arthritis Research & Therapy*. 21: Article number: 255, 2019.
- 2020
- 456) Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D,

- Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. *Invest New Drugs*. 38: 445-456, 2020.
- 457) Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Koichi M, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR: NEJ009 Study. *J Clin Oncol*. 38(2):115-123, 2020.
- 458) Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide, and trastuzumab for HER2-positive operable breast cancer: The JBCRG-10 study. *Jp J Clin Oncol*. 50: 3-11, 2020.
- 459) Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. *Investigational New Drugs*. 38: 445-456, 2020.
- 460) Ito H, Nakayama H, Yokose T, Nagashima T, Moroboshi T, Tajiri M, Maehara T, Watanabe K, Arai H, Yamamoto T, Woo T, Nishii T, Ishikawa Y, Morita S, Masuda M. A prophylaxis study of acute exacerbation of interstitial pneumonia after lung cancer surgery. *Jpn J Clin Oncol*. 50: 198-205, 2020.
- 461) Sunami E, Kusumoto T, Ota M, Sakamoto Y, Yoshida K, Tomita N, Maeda A, Teshima J, Okabe M, Tanaka C, Yamauchi J, Itabashi M, Kotake K, Takahashi K, Baba H, Boku N, Aiba K, Ishiguro M, Morita S, Takenaka N, Okude R, Sugihara K. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as postoperative adjuvant chemotherapy in patients with high-risk stage III colon cancer (ACTS-CC 02): a randomized, open-label, multicenter, phase 3, superiority trial. *Clinical Colorectal Cancer*. 19: 22-31, 2020.
- 462) Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Clinical outcomes of second-line chemotherapy in patients with previously treated advanced thymic carcinoma: a retrospective analysis of 191 patients from the NEJ023 study. *The Oncologist*. 25: e668-e674, 2020.
- 463) Takeda K, Morita S, Taguri M. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes. *Pharm Stat*. 19: 335-349, 2020.

- 464) Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. *Cancer Medicine*. 9: 1779-1789, 2020.
- 465) Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. *Int J Clin Oncol*. 24: 731-770, 2019.
- 466) Morino K, Seo S, Yoh T, Fukumitsu K, Ishii T, Taura K, Morita S, Kaido T, Uemoto S. Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on the Results of Locoregional Treatment: A Propensity Score-Stratified Analysis. *Annals of Surgical Oncology*. 27: 1908-1917, 2020.
- 467) Murakami I, Murakami K, Hashimoto M, Tanaka M, Ito H, Fujii T, Torii M, Ikeda K, Kuwabara A, Tanaka K, Yoshida A, Akizuki S, Nakashima R, Yoshifuji H, Ohmura K, Usui T, Morita S Mimori T. Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. *PLOS One*. 15: e0228852, 2020.
- 468) Tokudome N, Koh Y, Akamatsu H, Fujimoto D, Okamoto I, Nakagawa K, Hida T, Imamura F, Morita S, Yamamoto N. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. *BMC Cancer*. 20:103, 2020. DOI:10.1186/s12885-020-6593-1
- 469) Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, Toi M. Outcomes of Trastuzumab Therapy in HER2-Positive Early Breast Cancer Patients: Extended Follow-up of JBCRG-Cohort Study 01. *Breast Cancer* 27: 631-641, 2020.
- 470) Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T. Darbepoetin Alfa in Patients with Advanced CKD Without Diabetes: Randomized Controlled Trial. *Clin J Am Soc Nephrol*. 15: 608-615, 2020.
- 471) Ikeda H, Muraoka Y, Sumi E, Ikeda T, Nakagawa T, Abe H, Tada H, Hata M, Morita S, Kakaizuka A, Yoshimura N, Tsujikawa A. Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial. *PLOS ONE*. 15(2): e0229068, 2020. DOI:10.1371/journal.pone.0229068

- 472) Hattori Y, Kono Y, Itoh S, Nishino K, Kumagai T, Inoue T, Kawa Y, Urata Y, Tohrai R, Tamiya M, Kunimasa K, Uozumi R, Morita S, Negoro S, Imamura F, Satouchi M. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer. *BMC Cancer*. 20: 115, 2020. DOI:10.1186/s12885-020-6588-y
- 473) Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ota K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. *Annals of Hematology*. 99(5):1063-1072, 2020.
- 474) Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. *Breast Cancer Research and Treatment*. 180(3):715-724, 2020.
- 475) Nishikawa K, Murotani K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Hasegawa H, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: exploratory analysis of the randomized phase III TRICS trial. *Eur J Cancer*. 132: 159-167, 2020.
- 476) Takazawa A, Morita S. Optimal decision criteria for the study design and sample size of a biomarker-driven phase III trial. *Ther Innov Regul Sci*. 54: 1018-1034, 2020.
- 477) Matsumoto T, Murase K, Tabara Y, Minami T, Kanai O, Takeyama H, Takahashi N, Hamada S, Tanizawa K, Wakamura T, Komenami N, Setoh K, Kawaguchi T, Tsutsumi T, Morita S, Takahashi Y, Nakayama T, Hirai T, Matsuda F, Chin K. Sleep disordered breathing and metabolic comorbidities across gender and menopausal status in East Asians; the Nagahama Study. *Eur Respir J*. 2020; 56:1902251
- 478) Aoyama T, Morita S, Kono T, Hata T, Mishima H, Sakamoto J. Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group 12-item neurotoxicity questionnaire (FACT-GOG-NTX-12) in a phase 2, multicenter, randomized, double-blind, placebo-controlled trial. *Journal of Cancer Research and Therapeutics*, DOI:

10.4103/jert.JCRT_1123_19, 2020.

- 479) Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I. A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). *Cancer* 126: 3648-3656, 2020.
- 480) Ollier A, Morita S, Ursino M, Zohar S. An adaptive power prior for sequential clinical trials – Application to bridging studies. *Stat Methods Med Res.* 29: 2282-2294; 2020.
- 481) Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. *Breast Cancer.* 27: 389-398, 2020.
- 482) Sakamoto K, Honda G, Beppu T, Kotake K, Yamamoto M, Takahashi K, Endo I, Hasegawa K, Itabashi M, Hashiguchi Y, Kotera Y, Kobayashi S, Yamaguchi T, Tabuchi K, Kobayashi H, Yamaguchi K, Morita S, Miyazaki M, Sugihara K. Comprehensive data of 3525 patients newly diagnosed with colorectal liver metastasis between 2013 and 2014: 2nd report of a nationwide survey in Japan. *J Hepatobiliary Pancreat Sci.* 27: 555-562, 2020.
- 483) Oshima T, Yoshikawa T, Miyagi Y, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Tsuburaya A, Masuda M, Sakamoto J. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. *Oncotarget* 11: 2906-2918, 2020.
- 484) Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase Y, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K on behalf of the Kanto CML and Shimousa Hematology Study Groups. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission. *Cancer Sci.* 111: 2923-2934, 2020.
- 485) Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunozuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Evaluation of plasma EGFR mutation as an early predictor of response to erlotinib plus bevacizumab treatment in the NEJ026 study. *EBioMedicine.* doi: 10.1016/j.ebiom.2020.102861. Epub 2020.

- 486) Murakami K, Hamaji M, Morita S, Ueno K, Nakajima D, Ohsumi A, Menju T, Date H. Prolonged air leak after reoperative pulmonary resection (with prior ipsilateral chest surgery). *Interact Cardiovasc Thorac Surg.* 31: 544-546, 2020.
- 487) Sawada Y, Sahara K, Endo I, Sakamoto K, Honda G, Beppu T, Kotake K, Yamamoto M, Takahashi K, Hasegawa K, Itabashi M, Hashiguchi Y, Kotera Y, Kobayashi S, Yamaguchi T, Tabuchi K, Kobayashi H, Yamaguchi K, Morita S, Natsume S, Miyazaki M, Sugihara K. Long term outcome of liver resection for colorectal metastases in presence of extrahepatic disease: a multi-institutional Japanese study. *Journal of Hepato-Biliary-Pancreatic Sciences. J Hepatobiliary Pancreat Sci.* 27: 810-818, 2020.
- 488) Hosokawa A, Yamazaki K, Matsuda C, Ueda S, Fujii H, Baba E, Okamura S, Tsuda M, Tamura T, Shinozaki K, Tsushima T, Tsuda T, Shirakawa T, Yamashita H, Morita S, Hironaka S, Muro K. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: a post hoc analysis of the WJOG4407G phase III study. *Medicine (Baltimore).* 99: e22060, 2020.
- 489) Sakamoto T, Hida K, Hoshino N, Yamaguchi T, Manaka D, Yamada M, Kadokawa Y, Yamanokuchi S, Kondo M, Terajima H, Abe H, Morita S, Sakai Y. Changes in the sexual function of male patients with rectal cancer over a two-year period from diagnosis to 24-month follow-up: A prospective, multi-centre, cohort study. *J Surg Oncol. J Surg Oncol.* 122: 1647-1654, 2020.
- 490) Tsuda Moe, Ishiguro H, Toriguchi N, Masuda N, Bando H, Oogami M, Homma M, Morita S, Yamamoto N, Kuroi K, Yanagita Y, Takano T, Shimizu S, Toi M. Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. *Cancer Med.* 9: 9246-9255, 2020.
- 491) Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Disagreement between patients- and physicians-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. *Cancer Med.* 9: 9419-9430, 2020.
- 492) Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Bevacizumab as first-line Treatment for HER2-negative advanced breast cancer: Paclitaxel plus bevacizumab versus other chemotherapy. *In Vivo.* 1377-1386, 2020.
- 2021
- 493) Morita S, Mueller P, Abe H. A semiparametric Bayesian approach to population finding with time-to-event and toxicity data in a randomized clinical trial. *Biometrics.* 77: 634-648,

2021.

- 494) Hamaji M, Koyasu S, Omasa M, Nakakura A, Morita S, Nakagawa T, Miyahara S, Miyata R, Yokoyama Y, Kawakami K, Suga M, Takahashi M, Terada Y, Muranishi Y, Miyahara R, Sumitomo R, Huang CL, Aoyama A, Takahashi Y, Date H. Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrences after resection in patients with thymic carcinoma? *Surg Today*. 51: 322-326, 2021.
- 495) Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. *Breast Cancer*. 28: 145-160, 2021.
- 496) Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinamii T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: A multicenter, unilateral, open-label, phase II study (JBCRG M03 study). *Invest New Drugs*. 39: 217-225, 2021.
- 497) Minami T, Matsumoto T, Tabara Y, Gozal D, Smith D, Murase K, Tanizawa K, Takahashi N, Nakatsuka Y, Hamada S, Handa T, Takeyama H, Oga T, Nakamoto I, Wakamura T, Komenami N, Setoh K, Tsutsumi T, Kawaguchi T, Kamatani Y, Takahashi Y, Morita S, Nakayama T, Hirai T, Matsuda F, Chin K on behalf of the Nagahama Study group. Impact of sleep disordered breathing on glucose metabolism among individuals with a family history of diabetes: the Nagahama Study. *J Clin Sleep Med*. 17: 129-140, 2021.
- 498) Hamatani Yasuhiro, Iguchi M, Ueno K, Aono Y, Esato M, Tsuji H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M. Cardiology Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. *Heart*. 107: 705-712, 2021.
- 499) Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. A randomized phase II study of osimertinib with or without bevacizumab in EGFR-mutated NSCLC patients who were progressed with prior EGFR-TKI and acquired EGFR T790M mutation; West Japan Oncology Group 8715L study. *JAMA Oncol* (in press)
- 500) Fujitani K, Shitara K, Takashima A, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Hosaka H, Komatsu Y, Shimada K, Kawabata R, Ohdan H, Kodera Y, Nakamura M, Nakajima T, Miyata Y, Moriwaki T, Kusumoto T, Nishikawa K, Ogata K, Shimura M, Morita S, Koizumi W. Effect of early tumor response on the health-related

- quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. *Gastric Cancer*. 24: 467-476, 2021.
- 501) Fukuhara S, Asai K, Kakeno A, Umebachi C, Yamanaka S, Watanabe T, Yamazaki T, Nakao K, Setoh K, Kawaguchi T, Morita S, Nakayama T, Matsuda F, Bessho K; Nagahama Study Group. Association of education and depressive symptoms with tooth loss. *J Dent Res*. 100: 361-368, 2021.
- 502) Hamatani Y, Iguchi M, Ueno K, Aono Y, Esato M, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M. Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. *Heart* 2021 107: 705-712, 2021.
- 503) Toh Y, Hagihara A, Shiotani M, Onozuka D, Yamaki C, Shimizu N, Morita S, Takayama T. Employing multiple-attribute utility technology to evaluate publicity activities for cancer information and counselling programs in Japan. *J Cancer Policy*. 27: 100261, 2021.
- 504) Nishizaki D, Hida K, Sakai Y, Konishi T, Akiyoshi T, Maruyama S, Okajima M, Miyakura Y, Yamamoto S, Morita S, Watanabe M, on behalf of Japan Society of Laparoscopic Colorectal Surgery. Laparoscopic versus open surgery for advanced low rectal cancer: five-year survival outcomes in a large, multicenter, propensity score matched cohort study. *Dis Colon Rectum*. doi: 10.1097, 2021.
- 505) Ono A, Murakami H, Seto T, Shimizu T, Watanabe S, Takeshita S, Takeda K, Toyoshima J, Nagase I, Bahceci E, Morishita M, Morita S, Fukuoka M, Nakagawa K. Safety and antitumor activity of repeated ASP3026 administration in Japanese patients with solid tumors: A phase I study. *Drugs R D*. 21: 65-78, 2021.
- 506) Yang JCH, Mok TSK, Lu S, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo R, Morita S, Tamura T. Efficacy and safety of S-1 compared with docetaxel in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC trial. *JTO Clin Res Rep*. 2: 100142, 2021.
- 507) Tsubata Y, Shinomiya S, Inoue K, Ishikawa N, Saito R, Nakashima K, Hotta K, Hamada A, Nagashima F, Ando Y, Morita S, Kobayashi K, Isobe T. Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study. *BMC Geriatr*. 21: 74, 2021.
- 508) Watanabe J, Sasaki S, Kusumoto T, Sakamoto Y, Yoshida K, Tomita N, Maeda A, Teshima J, Yokota M, Tanaka C, Yamauchi J, Uetake H, Itabashi M, Takahashi K, Baba H, Kotake K, Boku N, Aiba K, Morita S, Takenaka N, Sugihara K. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as postoperative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase 3 ACTS-CC 02 trial. *ESMO Open*. 6: 100077, 2021.
- 509) Yamamoto S, Narui K, Ishikawa T, Adachi S, Yamada A, Shimada K, Shimizu D, Tanabe

- M, Oba M, Morita S, Sugae S, Doi T, Hasegawa S, Morita T, Kito A, Chishima T, Ichikawa Y, Endo I. First-line Gemcitabine versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study. *Anticancer Res.* 41: 1671-1676, 2021.
- 510) Ollier A, Zohar S, Morita S, Ursino M. Estimating similarity of dose-response relationships in phase I clinical trials - case study in bridging data package. *Int J Environ Res Public Health.* 18: 1639, 2021.
- 511) Watanabe K, Sunami E, Kusumoto T, Ota M, Sakamoto Y, Yoshida K, Tomita N, Maeda A, Teshima J, Okabe M, Tanaka C, Yamauchi J, Itabashi M, Kotake K, Takahashi K, Baba H, Boku N, Aiba K, Ishiguro M, Morita S, Takenaka N, Okude R, Sugihara K. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as postoperative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial. *ESMO Open* 6: 100077, 2021..
- 512) Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C. Advanced colorectal cancer subtypes (aCRCS) helps select oxaliplatin- or irinotecan-based therapy for colorectal cancer. *Cancer Sci* 112: 1567-1578, 2021.
- 513) Kim SY, Lee JS, Kang J, Morita S, Park YS, Sakamoto J, Muro K, Xu RH, Kim TW. Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase 3 trial (AXEPT). *The Oncologist.* doi: 10.1002/onco.13735. 2021.
- 514) Himoto Y, Lakhman Y, Fujii S, Morita S, Mueller JJ, Leitao MM Jr, Kido A. Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer. *Abdom Radiol (NY).* doi: 10.1007/s00261-021-03050-7. 2021.
- 515) Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A. A phase II study of first-line afatinib for patients aged 75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. *BMC Cancer.* 21: 208, 2021.
- 516) Beppu T, Imai K, Honda G, Sakamoto K, Kobayashi S, Endo I, Hasegawa K, Kotake K, Itabashi M, Hashiguchi Y, Kotera Y, Tabuchi K, Kobayashi H, Yamaguchi K, Morita S, Kikuchi K, Miyazaki M, Sugihara K, Yamamoto M, Takahashi K. Proposal of a novel H category-based classification of colorectal liver metastases based on a Japanese nationwide survey. *J Hepatobiliary Pancreat Sci* 28: 317-326, 2021.
- 517) Hamaji M, Omasa M, Nakanishi T, Nakakura A, Morita S, Miyamoto E, Nakagawa T, Miyahara S, Sonobe M, Takahashi M, Terada Y, Sumitomo R, Huang CL, Hijiya K, Kojima

- F, Shoji T, Date N, Miyata R, Suga M, Nakanobo R, Kawakami K, Aoyama A, Date H. Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas. *Interact Cardiovasc Thorac Surg*. 33: 242-249 2021.
- 518) Noda K, Kawai K, Matsuura Y, Ito-Ihara T, Amino Y, Ushimaru M, Kinoshita A, Tada H, Abe H, Morita S, Shimizu A, Tsuge I, Sakamoto M, Morimoto N. Safety of silk-elastin sponges in patients with chronic skin ulcers: A phase I/II, single-center, open-label, single-arm clinical trial. *Plast Reconstr Surg Glob Open* 9: e3556, 2021
- 519) Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai S, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka T, Uozumi R, Ohno S, Toi M. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer: a multicenter randomized phase II clinical trial. *Breast Cancer Res Treat* 188: 117-131, 2021.
- 520) Yoneshima Y, Morita S, Ando M, Nakamura A, Yoshioka H, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer. *J Thorac Oncol*. 16: 1523-1532, 2021.
- 521) Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: A randomized phase II study (JBCRG-19). *Int J Clin Oncol*. 26: 1229-1236, 2021.
- 522) Hida K, Nishizaki D, Sumii A, Okamura R, Sakai Y, Konishi T, Akagi T, Yamaguchi T, Akiyoshi T, Fukuda M, Yamamoto S, Arizono S, Uemura M, Hasegawa H, Kawada K, Morita S, Watanabe M. Prognostic impact of lateral pelvic node dissection on the survival of patients in low rectal cancer subgroups based on lymph node size. *Ann Surg Oncol* 28: 6179-6188, 2021.
- 523) Nishimura M, Sakai H, Onoe T, Boku S, Yokoyama T, Kadokura G, Morita S, Katsumata N, Matsumoto K. 4-step 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study. *Int J Clin Oncol* 26: 1553-1560, 2021.
- 524) Nakatsuka Y, Murase K, Matsumoto T, Tabara Y, Nakamoto I, Minami T, Takahashi N, Takeyama H, Kanai O, Hamada S, Tanizawa K, Handa T, Wakamura T, Komenami N, Morita S, Nakayama T, Hirai T, Matsuda F, Chin K. Markers of cardiovascular disease risk in sleep disordered breathing with or without comorbidities: the Nagahama Study. *J Clin Sleep Med*. 17: 2467-2475, 2021.
- 525) Kuroda Y, Tanaka T, Miyagawa T, Hamada H, Abe H, Ito-Ihara T, Asada R, Fujimoto Y, Takahashi D, Tetsunaga T, Kaneuji A, Takagi M, Inaba Y, Morita S, Sugano N, Tanaka S,

- Matsuda S, Akiyama H; TRION trial collaborators. Recombinant human FGF-2 for the treatment of early-stage osteonecrosis of the femoral head. *Regen Med* 16: 535-548, 2021.
- 526) Asada R, Abe H, Hamada H, Fujimoto Y, Choe H, Takahashi D, Ueda S, Kuroda Y, Miyagawa T, Yamada K, Tanaka T, Ito J, Morita S, Takagi M, Tetsunaga T, Kaneuji A, Inaba Y, Tanaka S, Matsuda S, Sugano N, Akiyama H. Femoral head collapse rate in Japanese patients with pre-collapse osteonecrosis of the femoral head. *J Int Med Res* 49: 3000605211023336, 2021.
- 527) Kondo T, Banno H, Okunomiya T, Amino Y, Endo K, Nakakura A, Uozumi R, Kinoshita A, Tada H, Morita S, Ishikawa H, Shindo A, Yasuda K, Taruno Y, Maki T, Suehiro T, Mori K, Ikeda M, Fujita K, Izumi Y, Kanemaru K, Ishii K, Shigenobu K, Kutoku Y, Sunada Y, Kawakatsu S, Shiota S, Watanabe T, Uchikawa O, Takahashi R, Tomimoto H, Inoue H. Repurposing bromocriptine for A β metabolism in Alzheimer's disease (REBRAnD) study: Double-Blind Comparative Trial and Open-Label Extension Trial to Investigate the Safety and Efficacy of bromocriptine in Alzheimer's Disease with Presenilin 1 (PSEN1) Mutations. *BMJ Open* 11: e051343, 2021.
- 528) Iwasa S, Muro K, Morita S, Park YS, Nakamura M, Kotaka M, Nishina T, Matsuoka H, Ahn JB, Lee KW, Hong YS, Han SW, Cho SH, Zhang DS, Fang WJ, Bai L, Yuan XL, Yuan Y, Yamada Y, Sakamoto J, Kim TW. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. *Cancer Sci.* 112: 4669-4678, 2021.
- 529) Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Sugauma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M. Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). *Cancers (Basel)*. 13: 4008, 2021.
- 530) Tanaka Y, Takeuchi H, Nakashima Y, Nagano H, Ueno T, Tomizuka K, Morita S, Emi Y, Hamai Y, Hihara J, Saeki H, Oki E, Kunisaki C, Otsuji E, Baba H, Matsubara H, Maehara Y, Kitagawa Y, Yoshida K. Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5). *ESMO Open*. 6: 100277, 2021.
- 531) Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda N. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). *Breast Cancer Res Treat.* 190: 425-434, 2021.

- 532) Fukuhara S, Asai K, Fukuhara T, Kakeno A, Yamanaka S, Nakao K, Watanabe T, Takahashi K, Yamazaki T, Umebachi C, Kashiwagi M, Setoh K, Kawaguchi T, Tabara Y, Morita S, Nakayama T, Matsuda F, Nakao K, Bessho K. Association between tooth loss and longitudinal changes in B-type natriuretic peptide over 5 years in postmenopausal women: The Nagahama Study. *Curr Probl Cardiol.* 100997, 2021.
- 533) Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, Katai H, Watanabe M, Seto Y, Hoon Noh S, Kwang Yang H, Ji J, Baba H, Kitagawa Y, Morita S, Nishiyama M, Kodera Y; CONVO - GC - 1 Study Group, Federation of Asian Clinical Oncology (FACO). International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). *Ann Gastroenterol Surg.* 6: 227-240, 2021.
- 534) Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study. *Sci Rep.* 11: 21454, 2021.
- 535) Rokutan-Kurata M, Yoshizawa A, Ueno K, Nakajima N, Terada K, Hamaji M, Sonobe M, Menju T, Date H, Morita S, Haga H. Validation Study of the IASLC Histological Grading System of Invasive Lung Adenocarcinoma *J Thorac Oncol.* 16: 1753-1758, 2021.
- 2022
- 536) Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunozuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. *Lancet Respir Med.* 10: 72-82, 2022.
- 537) Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. *BJU Int.* 130: 226-234, 2022.
- 538) Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed

using propensity score matching. *J Geriatr Oncol.* 13: 88-93, 2022.

- 539) Murase K, Matsumoto T, Tabara Y, Ohler A, Gozal D, Minami T, Kanai O, Takeyama H, Takahashi N, Hamada S, Tanizawa K, Wakamura T, Komenami N, Setoh K, Kawaguchi T, Tsutsumi T, [Morita S](#), Takahashi Y, Nakayama T, Yanagita M, Hirai T, Matsuda F, Chin K. Association of Sleep-disordered Breathing and Blood Pressure with Albuminuria: The Nagahama Study. *Ann Am Thorac Soc.* 19: 451-461, 2022.
- 540) Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, [Morita S](#), Ogawa O, Nishiyama H, Kitamura H, Sugimoto M; Japan Urological Oncology Group. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. *Urol Oncol.* 40: 107. e1-107.e9, 2022.
- 541) Kang YK, [Morita S](#), Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Chen LT, Boku N. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. *Gastric Cancer.* 25: 207-217, 2022.
- 542) Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, [Morita S](#), Kobayashi K, Isobe T. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). *Int J Clin Oncol.* 27: 112-120, 2022.
- 543) Takahashi N, Matsumoto T, Nakatsuka Y, Murase K, Tabara Y, Takeyama H, Minami T, Hamada S, Kanai O, Tanizawa K, Nakamoto I, Kawaguchi T, Setoh K, Tsutsumi T, Takahashi Y, Handa T, Wakamura T, Komenami N, [Morita S](#), Hirai T, Matsuda F, Nakayama T, Chin K; Nagahama Study Group. Differences between subjective and objective sleep duration according to actual sleep duration and sleep-disordered breathing: the Nagahama Study. *J Clin Sleep Med.* 18: 851-859, 2022.
- 544) Motoo Y, Shinozaki K, Takagi T, Ito S, Fujita H, Munemoto Y, Yoshida N, Baba E, Shindo Y, Miura M, [Morita S](#), Tsuji A. Evaluation of the efficacy and safety of an extract of the Japanese herbal medicine ninjin'yoeito combined with the CapeOX plus bevacizumab regimen in patients with advanced or recurrent colorectal cancer, with a special reference to nutritional status: A multicenter, randomized, open-labeled controlled trial (NYX study). *Medicine* (in press)

- 545) Akazawa R, Takeda K, [Morita S](#), Uegaki K. An example of planning, conducting, and decision making in an oncology dose-finding trial 5 with expansion cohorts. *Bulletin of the Biometric Society of Japan* (in press)
- 546) Yutaka Y, Sato T, Tanaka S, Miyahara S, Yoshizawa A, [Morita S](#), Date H. Feasibility study of a novel wireless localization technique using radiofrequency identification markers for small and deeply located lung lesions. *JTCVS Tech.* 12: 185-195, 2022.
- 547)
- 548) Ueki K, Matsuo Y, Takeda A, [Morita S](#), Taguri M, Kishi N, Hanazawa H, Tsurugai Y, Mizowaki T. Impact of local recurrence on cause-specific death after stereotactic body radiotherapy for early-stage non-small cell lung cancer: dynamic prediction using landmark model. *Int J Radiat Oncol Biol Phys* (in press)
- 549) Nakamoto S, Watanabe J, Ohtani S, [Morita S](#), Ikeda M. Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: A multicenter retrospective study. *BMC Cancer* (in press)
- 550) Matsumura M, Hasegawa K, Oba M, Yamaguchi K, Uetake H, Yoshino T, [Morita S](#), Takahashi K, Unno M, Shimada Y, Muro K, Yoshida K, Mori M, Baba H, Shimada M, Mise Y, Kawaguchi Y, Kagimura T, Ishigure K, Saiura A, Sugihara K, Kokudo N. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. *Langenbecks Archives of Surgery* (in press)
- 551) Hamada S, Handa T, Tanabe N, Sato S, Tanizawa K, Sato A, [Morita S](#), Chin K, Hirai T. Accuracy of respiratory rate surveillance using a home oxygen monitoring device among patients with interstitial lung disease and chronic obstructive pulmonary disease. *Sarcoidosis, Vasculitis and Diffuse Lung Diseases* (in press)
- 552) Taura K, Shimamura T, Akamatsu N, Umeshita K, Fujiyoshi M, Abe H, [Morita S](#), Uemoto S, Eguchi S, Furukawa H, Takada Y, Egawa H, Ohdan H, Hatano E; Japanese Liver Transplantation Society. No impact of donor sex on the recurrence of hepatocellular carcinoma after liver transplantation. *J Hepatobiliary Pancreat Sci.* 29: 570-584, 2022.
- 553) Sadahiro S, Sakamoto K, Tsuchiya T, Takahashi T, Ohge H, Sato T, Kondo K, Ogata Y, Baba H, Itabashi M, Ikeda M, Hamada M, Maeda K, Masuko H, Takahashi K, Sakamoto J, Kusano M, Hyodo I, Taguri M, [Morita S](#). Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). *BMC Cancer.* 22: 170, 2022.
- 554) Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, [Morita S](#), Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S. Factors

associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study. *Jpn J Clin Oncol.* 52: 545-553, 2022.

- 555) Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. *BMC Med.* 20: 136, 2022.
- 556) Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. *Lancet Oncol.* 23: 636-649, 2022.
- 557) Takeda K, Morita S, Taguri M. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy end toxicity in early clinical trials. *Biometrical Journal.* 64: 1178-1191, 2022.
- 558) Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study. *Jpn J Clin Oncol.* 52: 545-553, 2022.
- 559) Matsuo Y, Hiraoka M, Karasawa K, Kokubo M, Sakamoto T, Mukumoto N, Nakamura M, Morita S, Mizowaki T. Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors. *Radiother Oncol.* 172: 18-22, 2022.
- 560) Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Updated Analysis of NEJ009: Gefitinib-alone versus gefitinib plus chemotherapy for non-small cell lung cancer with mutated EGFR. *J Clin Oncol.* 40: 3587-3592, 2022.
- 561) Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Impact of early tumor shrinkage on quality of life in

- patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. *BMC Cancer*. 22: 711, 2022.
- 562) Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S.. Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS). *Cancer Sci*. 113: 3169-3179, 2022.
- 563) Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Morita S, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y, Takeuchi O. Regnase-1 Prevents Pulmonary Arterial Hypertension via mRNA Degradation of IL-6 and PDGF in Alveolar Macrophages. *Circulation*. 146: 1006-1022, 2022.
- 564) Murase K, Minami T, Hamada S, Gozal D, Takahashi N, Nakatsuka Y, Takeyama H, Tanizawa K, Endo D, Akahoshi T, Moritsuchi Y, Tsuda T, Toyama Y, Ohi M, Tomita Y, Narui K, Matsuyama N, Ohdaira T, Kasai T, Tsuboi T, Gon Y, Yamashiro Y, Ando S, Yoshimine H, Takata Y, Yoshihisa A, Tatsumi K, Momomura SI, Kuroda T, Morita S, Nakayama T, Hirai T, Chin K. Multimodal telemonitoring for weight reduction in sleep apnea patients: A randomized controlled trial. *Chest*. 162: 1373-1383, 2022.
- 565) Otsuka H, Kita Y, Ito K, Sano T, Inokuchi J, Tomida R, Takahashi A, Matsumoto K, Kurahashi R, Ozaki Y, Uegaki M, Maruyama S, Mukai S, Tsutsumi M, Kawahara T, Segawa T, Kitamura H, Morita S, Kobayashi T. Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias. *Cancer Sci*. 113: 3912-3921, 2022.
- 566) Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. Nab-paclitaxel for previously treated advanced non-small cell lung cancer: analysis of safety and efficacy in patients with renal impairment. *Clin Lung Cancer*. 23: 585-592, 2022.
- 567) Oi I, Ito I, Tanabe N, Konishi S, Hamao N, Shirata M, Imai S, Yasutomo Y, Kadowaki S, Matsumoto H, Hidaka Y, Morita S, Hirai T. Protein C activity as a potential prognostic factor for nursing home-acquired pneumonia. *PLOS ONE*. 17: e0274685, 2022.
- 568) Hisada T, Kondo N, Wanifuchi-Endo Y, Osaga S, Fujita T, Asano T, Uemoto Y, Nishikawa S, Katagiri Y, Terada M, Kato A, Sugiura H, Okuda K, Kato H, Komura M, Morita S, Takahashi S, Toyama T. Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ER α -positive breast cancer. *Sci Rep*. 12: 16515, 2022.
- 569) Najima Y, Tachibana T, Takeda Y, Koda Y, Aoyama Y, Toya T, Igarashi A, Tanaka M, Sakaida E, Abe R, Onizuka M, Kobayashi T, Doki N, Ohashi K, Kanamori H, Ishizaki T,

- Yokota A, Morita S, Okamoto S, Kanda Y. Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: A KSGCT prospective study. *Ann Hematol.* 101: 2719-2729, 2022.
- 570) Imamura K, Izumi Y, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Egawa N, Ayaki T, Oki R, Fujita K, Uozumi R, Morinaga A, Hirohashi T, Fujii Y, Yamamoto T, Tatebe H, Tokuda T, Takahashi N, Morita S, Takahashi R, Inoue H. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial. *eClinical Medicine.* 53: 101707, 2022.
- 571) Nagane M, Ichimura K, Onuki R, Narushima D, Honda-Kitahara M, Satomi K, Tomiyama A, Arai Y, Shibata T, Narita Y, Uzuka T, Nakamura H, Nakada M, Arakawa Y, Ohnishi T, Mukasa A, Tanaka S, Wakabayashi T, Aoki T, Aoki S, Shibui S, Matsutani M, Ishizawa K, Yokoo H, Suzuki H, Morita S, Kato M, Nishikawa R. Bevacizumab Beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. *Cancers (in press) Cancers (Basel).* 14: 5522, 2022.
- 572) Goto T, Kimura H, Yoshino T, Sawada A, Akamatsu S, Kobayashi T, Yamasaki T, Tazawa S, Fujimoto M, Hidaka Y, Uozumi R, Morita S, Ogawa O, Inoue T. Efficacy and safety of Brazilian green propolis in biochemically recurrent prostate cancer after radical prostatectomy: A single-arm phase II study. *International Journal of Translational Medicine.* 2, 618, 2022.
- 573) Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, Kato H, Yoshibayashi H, Suwa H, Tsuji W, Yamashiro H, Suzuki E, Torii M, Kataoka T, Ishiguro H, Morita S, Toi M. Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. *Sci Rep.* 12: 22397, 2022.
- 574) Yamamoto Y, Yamashiro H, Schneeweiss A, Müller V, Gluz O, Klare P, Aktas B, Magdolna D, Büdi L, Pikó B, Mangel L, Toi M, Morita S, Ohno S. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies. *Breast Cancer.* 30: 88-100, 2023.
- 575) Ohata K, Gonokami T, Kinjo S, Kato S, Morita S, Kobayashi K. Structure of spirituality among high-school students differs depending on relationship with someone or something greater (RSG). *Current Psychology* 42, 26709–26719, 2023.
- 576) Sakamoto K, Beppu T, Honda G, Kotake K, Yamamoto M, Takahashi K, Endo I, Hasegawa K, Itabashi M, Hashiguchi Y, Kotera Y, Kobayashi S, Yamaguchi T, Natsume S, Tabuchi K, Kobayashi H, Yamaguchi K, Tani K, Morita S, Miyazaki M, Sugihara K. Comprehensive data of 4,502 patients newly diagnosed with colorectal liver metastasis between 2015 and 2017,

and prognostic data of 2,427 patients newly diagnosed with colorectal liver metastasis between 2013 and 2014: Third report of a nationwide survey in Japan. *J Hepatobiliary Pancreat Sci.* 30: 570-590, 2023.

- 577) Katakami N, Yokoyama T, Morita S, Okamoto T, Urata Y, Hattori Y, Iwamoto Y, Sato Y, Ikeda N, Takahashi T, Daga H, Oguri T, Fujisaka Y, Nishino K, Sugawara S, Kozuki T, Oki M, Yamamoto N, Nakagawa K. Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for advanced lung adenocarcinoma (WJOG5108LFS). *Int J Clin Oncol.* 28: 79-88, 2023.
- 578) Matsumoto T, Murase K, Tabara Y, Minami T, Kanai O, Takeyama H, Sunadome H, Nagasaki T, Takahashi N, Nakatsuka Y, Hamada S, Handa T, Tanizawa K, Nakamoto I, Wakamura T, Komenami N, Setoh K, Kawaguchi T, Tsutsumi T, Morita S, Takahashi Y, Nakayama T, Sato S, Hirai T, Matsuda F, Chin K. Sleep disordered breathing and hemoglobin A1c levels within or over normal range and aging or sex differences: the Nagahama Study. *J Sleep Res.* 32: e13795, 2023.
- 579) Matsui K, Earashi M, Yoshikawa A, Fukushima W, Nozaki Z, Oyama K, Maeda K, Nakakura A, Morita S, Fujii T. Real-world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis. *Mol Clin Oncol.* 18: 12, 2023.
- 580) Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study. *Jpn J Clin Oncol.* 53: 203-211, 2023.
- 581) Beppu T, Yamamura K, Sakamoto K, Honda G, Kobayashi S, Endo I, Hasegawa K, Kotake K, Itabashi M, Hashiguchi Y, Kotera Y, Yamaguchi T, Natsume S, Tabuchi K, Kobayashi H, Yamaguchi K, Morita S, Kikuchi K, Miyazaki M, Sugihara K, Yamamoto M, Takahashi K; Joint Committee for Nationwide Survey on Colorectal Liver Metastasis. Validation study of the JSHBPS nomogram for patients with colorectal liver metastases who underwent hepatic resection in the recent era - a nationwide survey in Japan. *J Hepatobiliary Pancreat Sci.* 30: 591-601, 2023.
- 582) Ueno K, Morita S. Sensitivity analysis for restricted mean survival time when survival curves have divergent tails. *Therapeutic Innovation & Regulatory Science.* 57: 467-471, 2023.
- 583) Iwasa S, Wang ZX, Muro K, Morita S, Park YS, Yamada Y, Sakamoto J, Xu RH, Kim TW. Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study. *Cancer Commun (Lond).* 43: 519-522, 2023.

- 584) Jo N, Hidaka Y, Kikuchi O, Fukahori M, Sawada T, Aoki M, Yamamoto M, Nagao M, Morita S, Nakajima T, Muto M, Hamazaki Y. Impaired CD4+ T-cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. *Nat Aging*. 3: 82-92, 2023.
- 585) Miyanaga A, Asahina H, Watanabe S, Shukuya T, Isobe T, Hosomi Y, Sugawara S, Maemondo M, Okano T, Morita S, Matsuyama K, Kobayashi K, Seike M. A Phase I/II Study of necitumumab plus pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non-small cell lung cancer study: (NEJ048A/NEXUS). *Clin Lung Cancer*. 24: 371-375, 2023.
- 586) Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Trifluridine/tipiracil+bevacizumab (BEV) vs fluoropyrimidine irinotecan+BEV as second-line therapy for metastatic colorectal cancer-A randomized noninferiority trial. *Br J Cancer*. 128: 1897-1905, 2023.
- 587) Iizuka Y, Hiraoka M, Kokubo M, Sakamoto T, Karasawa K, Murofushi K, Nakamura M, Matsuo Y, Morita S, Inokuchi H, Mizowaki T. Dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring of liver tumors using a gimbal-mounted linac: A multi-institutional phase II study. *Clin Transl Radiat Oncol*. 39: 100591, 2023.
- 588) Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Morita S, Asahina H, Tanaka K, Sugio K, Kobayashi K. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. *Eur J Cancer*. 185: 83-93, 2023.
- 589) Song J, Morita S, Kuo YW, Lee JJ. BayesESS: A tool for quantifying the impact of parametric priors in Bayesian analysis. *SoftwareX*. 22: 101358, 2023.
- 590) Sugitani Y, Morita S, Nakakura A, Yamamoto H. Biomarker-based Bayesian randomized clinical trial design for identifying a target population. *Stat Med*. 42: 2797-2810, 2023.
- 591) Fujita K, Arai R, Shoji S, Saito R, Nomura M, Hotta T, Asahina H, Kawakami M, Nakachi I, Hasegawa Y, Okafuji K, Suzuki A, Miyanaga A, Sunaga N, Nagashima H, Ikeda N, Watanabe S, Nagai Y, Furuta M, Kage H, Arai D, Fukuhara T, Nakayama M, Morita S, Kobayashi K, Hagiwara K. Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: an Advanced Medicine A trial. *Cancer Sci*. 114: 3342-3351, 2023.
- 592) Yamamoto H, Soh J, Okumura N, Suzuki H, Nakata M, Fujiwara T, Gemba K, Sano I, Fujinaga T, Kataoka M, Terazaki Y, Fujimoto N, Kataoka K, Kosaka S, Yamashita M,

- Inokawa H, Inoue M, Nakamura H, Yamashita Y, Hotta K, Yoshioka H, Morita S, Matsuo K, Sakamoto J, Date H, Toyooka S. Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm) - IIIA of non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1201 (SLCG1201). *PLoS One*. 18: e0285273, 2023.
- 593) Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Torii M, Yakami M, Isoda H, Takakura K, Morita S, Takada M, Toi M, Nakamoto Y. Performance of dedicated breast PET in breast cancer screening: comparison with digital mammography plus digital breast tomosynthesis and ultrasound. *Ann Nucl Med*. 37: 479-493, 2023.
- 594) Maruyama S, Kurasawa S, Hayashi T, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial. *Clin Exp Nephrol*. 27: 757-766, 2023.
- 595) Katakami N, Nishimura T, Hidaka Y, Hata A, Nishino K, Mori M, Hirashima T, Takase N, Kaneda T, Ohnishi H, Morita S, Hatachi Y. Randomized phase II study of zoledronate dosing every 4 versus 8 weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312). *Lung Cancer*. 182: 107261, 2023.
- 596) Yoshida S, Kamada Y, Hida K, Okada K, Obama K, Morita S, Kitai T, Yonemura Y. Comparison of Cytoreductive Surgery and Resection of Isolated Peritoneal Metastases in Patients with Peritoneal Metastases from Colorectal Cancer: A Retrospective Study. *J Anus Rectum Colon*. 7: 91-101, 2023.
- 597) Takeda K, Yamaguchi Y, Taguri M, Morita S. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes. *Biometrical J*. DOI: 10.1002/bimj.202200265, 2023.
- 598) Kaneko Y, Morita S. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials. *J Biopharm Stat*. Aug 10: 1-20, 2023.
- 599) Yamanaka H, Sawaragi E, Nakano T, Katayama Y, Ito T, Tada H, Hidaka Y, Morita S, Funakoshi C, Kinoshita A, Watanabe M, Tsuge I, Katsube M, Sakamoto M, Yamaoka T, Morimoto N. A high-hydrostatic pressure device for nevus tissue inactivation and dermal regeneration for reconstructing skin defects after giant congenital melanocytic nevus excision: a clinical trial. *Regen Ther*. 24: 167-173, 2023.
- 600) Nakatsuka Y, Murase K, Sonomura K, Tabara Y, Nagasaki T, Hamada S, Matsumoto T, Minami T, Kanai O, Takeyama H, Sunadome H, Takahashi N, Nakamoto I, Tanizawa K, Handa T, Sato TA, Komenami N, Wakamura T, Morita S, Takeuchi O, Nakayama T, Hirai T, Kamatani Y, Matsuda F, Chin K. Hyperfructosemia in sleep disordered breathing:

metabolome analysis of Nagahama study. *Sci Rep.* 13: 12735, 2023.

- 601) Hattori S, Morita S. Frequentist analysis of basket trials with one-sample Mantel-Haenszel procedures. *Stat Med.* 42: 4824-4849, 2023.
- 602) Yao Z, Morita S. Bayesian predictive model averaging approach to joint longitudinal-survival modeling: Application to an immuno-oncology clinical trial. *Stat Med.* 42: 4990-5006, 2023.

[Review papers] (総説)

- 1) Morita S, Kaptein AA, Tsuburaya A, Kodera Y, Matsui T, Sakamoto J. Assessment and Data Analysis of Health-Related Quality of Life in Clinical Trials for Gastric Cancer Treatments. *Gastric Cancer.* 9: 254-261, 2006.
- 2) Hsu C, Liang PC, Morita S, Hu FC, Cheng AL. Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy. *Liver Cancer* 1: 168-176, 2012.
- 3) Tateishi U, Morita S, Inoue T. Diagnostic accuracy of ¹⁸F-fluoride PET and PET/CT in patients with bone metastases: a systematic review and meta-analysis update. *Clin Transl Imaging.* 1: 123-134, 2013.
- 4) Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura C, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Japanese Lung Cancer Society Guideline for stage IV non small cell lung cancer with epidermal growth factor receptor mutations. *JTO Clinical and Research Reports.* 2: 100107, 2021.

[Editorial]

Hamasaki T, Morita S, Chen J. Special Issue for selected articles from the ISBS2019: Statistical innovation and contribution in the era of precision healthcare. *Stat Bioparm Res* (in press)

[Case report](症例報告)

- 1) Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva OA, Furukawa Y, Tsukaguchi M, Shirakata T, Nishida S, Nakajima H, Morita S, Sakamoto J, Kawase I, Oji Y, Sugiyama H. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. *Int J Hematol* 85: 426-9, 2007.
- 2) Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S,

Sakamoto J, Udaka K, Kawase I, Sugiyama H. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. *International Journal of Hematology* 86: 414-7, 2007.

3) Watanabe T, Yoshikawa T, Kameda Y, Aoyama T, Hayashi T, Ogata T, Cho H, Tsuburaya A, Morita S, Miyashita Y, Sakamoto J. Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case. *Surgical Today*. 42: 983–987, 2012

[Textbooks] (著書)

- 1) Ishizuka N, Morita S. Practical Implementation of the Continual Reassessment Method. In: Crowley J eds. *Handbook of Statistics in Clinical Oncology, Second Edition*. New York: CRC Press, 97-116, 2005.
- 2) Morita S, Thall PF. Prior Effective Sample Size of a Bayesian Model. In: Chow SC eds. *Encyclopedia of Biopharmaceutical Statistics, 3rd Edition*. London: Informa Healthcare, 1066-1069, 2010.

[邦文論文]

- 1) 高橋奈津子、菊池臣一、福原俊一、鈴嶋よしみ、紺野慎一、森田智視、岩本幸英、中村孝志. 腰痛特異的QOL尺度：Roland-Morris Disability Questionnaireの性・年齢階層別基準値の測定. *臨床整形外科* 39: 315-319, 2004.
- 2) 野口海、大野達也、森田智視、相原興彦、辻井博彦、下妻晃二郎、松島英介. がん患者に対するFunctional Assessment of Cancer Therapy Spiritual(FACT-Sp)日本語版の信頼性・妥当性の検討(予備的調査). *癌と化学療法* 31: 387-391, 2004.
- 3) 野口海、大野達也、森田智視、相原興彦、辻井博彦、下妻晃二郎、松島英介. がん患者に対するFunctional Assessment of Chronic Illness Therapy –Spiritual(FACIT-Sp)日本語版の信頼性・妥当性の検討. *日本総合病院精神医学誌* 16: 42-48, 2004.
- 4) 森田智視、下妻晃二郎、佐藤 温、中町正俊、Jane Blazeby、Karen West、福原俊一、坂本純一. EORTC QOL調査票胃癌患者用モジュールSTO22(日本語版)の開発. *癌と化学療法* 31: 1195-1199, 2004.
- 5) 野口海、森田智視、大野達也、相原興彦、辻井博彦、下妻晃二郎、松島英介. がん患者のSpiritualityとロゴセラピーの有効性の検討 -FACIT-SpとPILテストAとの関連を中心に- *総合病院精神医学* 17: 42-47, 2005.
- 6) 荒田慎寿、森脇義弘、高山和久、森本学、沼田和司、田栗正隆、森田智視、今成秀則、田中克明. 急性肝不全に対する on-line hemodiafiltration を用いた人工肝補助療法の確立. *肝臓* 53, 7-17: 2012.

- 7) 永金義成, 田中瑛次郎, 濱中正嗣, 山田丈弘, 藤並潤, 岸谷融, 徳田直輝, 沼宗一郎, 森田智視, 山本康正. 急性期虚血性脳卒中患者における90日後の重篤な転帰の予測因子. 脳卒中. 11086, 1-7, 2023.

[総説その他]

- 1) 小林国彦, 手良向聡, 森田智視. がん医療におけるQOL研究の世界的動向ー肺癌を中心に. 血液・腫瘍科 41: 498-503, 2000.
- 2) 大橋靖雄, 森田智視. QOLデータの統計学的評価. 薬剤疫学 5: 71-82, 2001.
- 3) 森田智視, 福原俊一. 世界的統計調査DOPPSから見た腎不全患者のHRQOL. Nephrology Frontier 3: 31-34, 2004.
- 4) 森田智視, 松山裕. ランダム化比較試験における治療開始後変数で定義されるサブグループ間での平均因果効果の推定. SASユーザー会論文集 51-61, 2004.
- 5) 森田智視, 福原俊一. 生体15: QOL評価(アウトカム指標として). 臨床透析 21: 247-254, 2005.
- 6) 毛利光子, 広瀬奈津子, 福田敬, 大住省三, 向井博文, 森田智視, 今井博久, 渡辺亨, 下妻晃二郎, 大橋靖雄. 研究者主導がん臨床試験におけるコストデータ収集方法の検討. 薬剤疫学 10: S42-S43, 2005.
- 7) 森田智視, 大橋靖雄. 非小細胞肺癌患者におけるQOLの評価. 臨床研究・生物統計研究会誌 20: 54-59, 2005.
- 8) 坂本純一, 森田智視, 大庭幸治, 佐藤俊哉, 福井次矢, 萩原俊男, 北徹, 中尾一和, 猿田亨男. 高血圧に対する大規模臨床試験(CASE-J)の実践における諸問題. 臨床薬理 37: 93S-94S, 2006.
- 9) 坂本純一, 森田智視. 外来がん化学療法と外科-外来化学療法の今後. 臨床外科 62: 677-686, 2007.
- 10) 森田智視. がん早期臨床試験のデザインーベイズ流アプローチを中心としてー. 臨床研究・生物統計研究会誌, (2007)
- 11) 森田智視. 肺癌のUp-To-Date 肺癌臨床研究における生物統計. Lung Perspect 16: 499-502, 2008.
- 12) 森田智視. 適応的デザインの基礎理論と適用例. 計量生物学, 29: S53-S59, 2008.
- 13) 佐藤俊哉, 森田智視, 大庭幸司. CASE-Jにおける医療統計家の役割. 日本臨床 66: 51-55, 2008.
- 14) 浅野泰, 秋澤忠男, 福原俊一, 下條文武, 松尾清一, 頼岡徳在, 森田智視, 脇田貴文, 大西良浩, 黒川清. 慢性腎不全患者における経口吸着炭素製剤の腎不全進行抑制効果に関するRCT-慢性腎臓病における吸着炭素療法(CAP-KD)試験結果-. 日本腎臓学会誌 50: 528-531, 2008.
- 15) 坂本純一, 森田智視, 大庭幸治. 臨床評価法 DFSとOSの相関: 大腸がん補助化学療法

- surrogate endpointの探索と留意点-.月刊腫瘍内科 4: 433-444, 2009.
- 16) 森田智視. 新規薬剤に関する臨床試験デザイン. 「特集：腫瘍内科の現状と展開」.日本内科学会雑誌第 98: 1854-1859, 2009.
 - 17) 森田智視. 臨床試験におけるベイズ流統計学の利用：がん早期臨床試験におけるベイズ流統計学の利用. 臨床評価 38: 281-290, 2010.
 - 18) 森田智視. がん患者のサバイバーシップ QOLの評価とデータ解析. 月刊腫瘍内科 5: 107-111, 2010.
 - 19) 大島貴、藤井正一、高川亮、木村準、牧野洋知、小野秀高、秋山浩利、田栗正隆、森田智視、遠藤格. 胃癌に対する腹腔鏡下胃切除術と開腹胃切除術 - A Case-Control Study-. 癌の臨床 56: 863-868, 2010
 - 20) 森田智視. 新規抗がん剤の開発と導入 I：「がん化学療法の進歩」がん化学療法の整備に向けて. 化学療法の領域 27: 9-16, 2011.
 - 21) 大橋靖雄、森田智視. 第III相臨床試験の統計的側面 -Gemcitabine/TS-1膀胱癌第III相試験を事例として-. 肝胆膵 64: 203-208, 2012.
 - 22) 吉川 貴己, 桑原寛, 青山徹, 三箇山洋, 林勉, 尾形高士, 長晴彦, 円谷彰, 森田智視, 坂本純一. 胃癌補助化学療法の開発戦略. 日本外科系連合学会誌 37: 686-690, 2012.
 - 23) 川口淳, 森田智視. データの記述. 呼吸, Vol.34 No.3, 280-285, 2015.
 - 24) 武田健太郎, 大庭真梨, 柿爪智行, 坂巻顕太郎, 田栗正隆, 森田智視. 臨床試験におけるヒストリカルコントロールデータの利用. 計量生物学 36: 25-50, 2015.
 - 25) 相田麗, 今井匠, 廣田誠子, 田中司朗, 森田智視, 濱崎俊光, 佐藤俊哉. 臨床統計家育成の諸問題. 統計数理 66, 49-62, 2018.
 - 26) 森田智視. 臨床研究の医学統計におけるピットフォール. アレルギー, 67, 1003-1005, 2018.
 - 27) 森田智視. マイルストーン (milestone) 解析. 腫瘍内科, 19, 214-218, 2017.
 - 28) 森田智視. 生物統計学の基礎. 肺癌, 58, 891-893, 2018.
 - 29) 森田智視. がん臨床試験のエンドポイント：PFS2やQOLの活用について. 腫瘍内科, 23, 405-409, 2019.
 - 30) 坂巻顕太郎, 兼清道雄, 大和田章一, 松浦健太郎, 柿爪智行, 高橋文博, 高沢翔, 萩原駿祐, 森田智視. ベイズ流決定理論を用いる臨床試験：効用とサンプルサイズ設計. 計量生物学 41: 55-91, 2020.
 - 31) 森田智視. 生物統計家へのコンサルテーション. 整形外科, 71, 520-522, 2020.
 - 32) 森田智視. 生存曲線の基本とハザード比の考え方. 外科, 82, 805-809, 2020.
 - 33) 滝口裕一, 瀬戸貴司, 野崎要, 長谷川一男, 森田智視, 守田亮, 二宮貴一郎, 樋田豊明. 肺癌診療ガイドライン2020年改訂版-課題と将来-. 肺癌, 61, 163-170, 2021.

[著書]

- 1) 大橋靖雄, 森田智視. QOLの統計学的評価. 臨床のためのQOL評価ハンドブック. 医学書院 19-29, 2001.
- 2) 大橋靖雄, 森田智視. 臨床比較試験におけるQOLデータの解析. 新QOL調査票と評価の手引き. メディカルレビュー社 273-282, 2001.
- 3) 森田智視, 福原俊一. 予後予測因子としての健康関連QOL. 腎臓病: 先端医療シリーズ 31. 先端医療技術研究所 199-200, 2005.
- 4) 下妻晃二郎, 森田智視. QOL評価. 癌治療の新たな試み 新編III. 医薬ジャーナル社 714-736, 2005.
- 6) 坂本純一, 森田智視. 第VI章-抗癌剤の臨床第II,III相試験. 久保田哲朗, 大村健二(編), 消火器癌化学療法, 南山堂 407-414, 2009.